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ABSTRACT
The contributions made by mathematical approaches to biological problems has become
widely recognized in recent decades. The focus of this thesis is to develop and analyze novel
mathematical models for various aspects of three infectious diseases: Human Immunodefi-
ciency Virus (HIV), Ebola virus disease (EVD) and Zika virus. HIV is examined at the
in-host level by two models capturing two stages of the disease process within the blood. The
first HIV model considered here incorporates the effects of latent infection and mutation of
the virus. This research is meant to provide applicable information when considering various
vaccine developments and combination strategies to maintain viral suppression. The second
HIV model in this dissertation examines early stage viral development and the contribution
of the homeostatic proliferation of CD4+ T cells on the dynamics of the disease process; in
particular the dependence of long term outcomes on the initial viral load and healthy T cell
count. Both EVD and Zika are analyzed at the epidemiological level with compartmental
model structures. A branching SEIR Ebola model is embedded into a stochastic process by
means of a novel multinomial distribution derivation. This model is used to determine the
most prominent forces of infection causing the 2014 Ebola outbreak in West Africa based
on data as recorded by the World Health Organization. Finally, the spread of Zika within
Central and South American countries is modeled by way of a modified (SEIR)/SEI vector
compartmental structure to estimate basic reproductive numbers, total outbreak size, and
reporting rates for Colombia, El Salvador and Suriname. This study highlights the need
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The law of mass action is the proposition that the rate of a chemical reaction is directly
proportional to the product of the concentrations of the reactants [1]. This idea, which went
largely unnoticed when first proposed in 1864 by Norwegian mathematician and chemist
Cato Maximilian Guldberg, along with his brother in law and fellow chemist Peter Waage,
has been used in a wide range of applications. In this thesis, we employ the law of mass action
to model and gain insight into the progression of three diseases: Human Immunodeficiency
Virus (HIV), Ebola virus disease, and Zika virus. Modeling the dynamics of these diseases
by incorporating a mass action term has enabled, among other things, the development of
biological understanding of key components which drive the evolution of a disease in vivo,
and the quantification of rates of transmission of a disease among a population.
The course of an HIV infection is typically characterized with three stages based on the
population sizes of the healthy T cells, infected T cells and virions . The first stage, known
as the acute infection, is distinguished by a rapid fluctuation in both the healthy T cell and
virus populations usually lasting from 2 to 10 weeks [2]. Symptoms during this stage, often
described as flu-like symptoms, include fever, swollen glands, sore throat, rash, fatigue, etc.,
[3]. During the second stage, known as chronic infection or the asymptomatic period, HIV
reproduces at very low levels, although it is still active. The population sizes of healthy T
cells and viral load reach a relatively consistent quantity. This period, without treatment,
can last for 7 to 10 years but can vary greatly among individual patients [4]. The third
stage, the onset of AIDS, occurs when the virus population seems to grow exponentially
with a rapid decrease in the healthy T cell population. Once the T cell count is below 200
cells mm−3 or when certain associated infections are experienced, a patient is said to have
AIDS (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009). To capture
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the dynamics of the population sizes of the healthy T cells, infected T cells and viral load
within the blood of a patient the mass action term is applied. We assume that the rate at
which the number of newly infected T cells grows is a proportion of the product of the size
of the healthy T cell population and the viral load.
Ebola virus disease, or simply Ebola, belongs to a a group of viral infections characterized
by high fever, petechiae, internal bleeding, hypotension and shock [5]. Because the natural
reservoir host of Ebola viruses has not yet been identified, the source of Ebola epidemics
within the human population is unclear [5]. It is believed that the virus is transmitted to
humans by contact with an infected animal either by touch or ingestion. According to the
World Health Organization (WHO), Ebola is spread from human to human through direct
contact with blood or bodily fluids (including but not limited to urine, saliva, sweat, feces,
vomit, breast milk, and semen), and objects (like needles, syringes, bedsheets, etc.) that
have been contaminated with body fluids from a person who is sick or has died from Ebola.
The epidemiological study of this disease, within the thesis, uses a mass action term to
calculate the number of newly infected people among the population. We assume the spread
through contact is proportional to the product of the number of susceptible individuals and
the number of infectious individuals within the total population of interest.
In the Zika forest of Uganda in 1974, the Zika virus was first discovered in isolation from
a rhesus macaque. Since this time the virus has spread to the human population and across
continents to reach näıve populations that are unprepared to mitigate the viral spread. Zika
virus is transmitted to humans primarily through bites from infected Aedes aegypti and Aedes
albopictus mosquitoes. The transmission is in both directions, that is, infected mosquitoes
infect humans and infected humans infect mosquitoes. Once again, we exploit the mass action
term to describe the transmission between these populations. The number of newly infected
humans is proportional to the product of the number of susceptible humans and the number
of infected mosquitoes. Similarly, the number of newly infected mosquitoes is proportional
to the product of the number of susceptible mosquitoes and the number of infected humans.
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This proportion is called the force of infection term and can be approximated based on the
probability of an infectious bite occurring with successful transmission of the disease.
The investigation and application of the mass action term in modeling these diseases is
described in the duration of the thesis. The presentation of the methods and findings is
as follows. In Chapter 2, we develop a model of 7 ODEs, based on [6], with only thirteen
parameters to enable a thorough analysis of the first two stages of an HIV infection incor-
porating latent infection and viral mutation. In Chapter 3, we reduce a three stage model
proposed by [7] to a system of three ODEs to complete an analysis of an acute stage model
that describes the effects of homeostatic proliferation. The next mathematical analysis, in
Chapter 4, will be performed on a model of the 2014 Ebola outbreak in West Africa. The
event has been modeled using a deterministic system of ODEs [8] which we will embed into
a stochastic process to estimate parameters of interest through Bayesian inference. Chapter
5 contains the final analysis examining the 2015 Zika virus outbreak in Central and South
American countries. We will estimate the basic reproductive number, the reporting rate and
the total outbreak sizes.
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CHAPTER 2
AN IN-HOST MODEL OF HIV INCORPORATING LATENT INFECTION AND VIRAL
MUTATION
Modified from a paper published in the Proceedings of the 2014 AIMS Conference on
Differential Equations and Dynamical Systems.
Deborah Shutt1, Stephen Pankavich2
2.1 Abstract
We construct a seven-component model of the in-host dynamics of the Human Immun-
odeficiency Virus Type-1 (i.e, HIV) that accounts for latent infection and the propensity of
viral mutation. A dynamical analysis is conducted and a theorem is presented which char-
acterizes the long term behavior of the model. We study the effects of an antiretroviral drug
and treatment implications. Finally, a sensitivity analysis is performed to obtain an active
subspace by which the active variable vector can be identified to determine the parameters
that drive the behavior of the system studied.
2.2 Introduction
We develop a two-stage model of infection consisting of seven nonlinear ODEs that de-
scribe the increase in viral load stemming from latent (or dormant) infection and the ability
of HIV to escape the immune system due to viral mutation. The model is validated through
computational means and stability properties of all equilibria in the system were charac-
terized in terms of primary and secondary reproductive ratios. Additionally, we study the
control of infection through the use of antiretroviral drug therapy, in particular using a cat-
egory of drugs known as reverse transcriptase inhibitors (RTIs). Our analysis determines
1Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
2Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
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that a sufficiently high drug-resistance level arising from viral mutation could render a per-
sistent HIV infection untreatable, thereby displaying the long-term decrease in efficacy often
exhibited by RTIs used to treat HIV patients.
2.3 The Model
The following model describes the dynamics between healthy helper T cells, actively and
latently infected T cells, and wild-type and mutated virus populations of an HIV strain. This
model incorporates latent infection into a previously studied HIV model [6]. The model is
comprised of seven nonlinear and fully-coupled ordinary differential equations given by
dT
dt
= λ− dTT − ksTVs − krTVr (2.1)
dIs
dt
= (1− p)(1− µ)ksTVs + αsLs − dIIs (2.2)
dLs
dt
= p(1− µ)ksTVs − αsLs − dLLs (2.3)
dVs
dt
= NsdIIs − dV Vs (2.4)
dIr
dt
= (1− p)µksTVs + (1− p)krTVr + αrLr − dIIr (2.5)
dLr
dt
= pµksTVs + pkrTVr − αrLr − dLLr (2.6)
dVr
dt
= NrdIIr − dV Vr. (2.7)
Here, T denotes the population of healthy helper T cells. An estimated maturity rate
of helper T cells to immunocompetent T cells is represented by the parameter λ, and the
death rate of these T cells is denoted dT . The parameter ks is the rate of infection of
the wild-type HIV strain. The population of the wild-type strain is denoted by Vs. The
population of infected helper T cells by the wild-type HIV strain, ksTVs, will contribute to
several other populations. As mentioned before, an infected helper T cell can either become
latently or actively infected. We use p to represent the proportion of helper T cells which
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become latently infected and hence the terms (1− p)ksTVs and pksTVs are included within
equations (2.2) and (2.3) where Is and Ls denote the CD4
+ T cell populations that have
become actively or latently infected and produce or will produce the wild-type HIV virions,
respectively. However, our model also accounts for mutation of the wild-type provirus, and
thus the portion of T cells actively infected by the wild-type HIV strain, (1 − p)ksTVs, is
further divided into replicating wild-type and mutated virus populations. In the model, µ is
used to represent the rate of mutation and the terms (1− p)(1−µ)ksTVs and (1− p)µksTVs
are added to equations (2.2) and (2.5), where Ir denotes the CD4
+ T cell population actively
infected and producing mutated HIV virions. Helper T cells latently infected by the wild-
type HIV strain, pksTVs, may or may not create a mutated provirus and thus the terms
p(1− µ)ksTVs and pµksTVs are included in equations (2.3) and (2.6), where Lr denotes the
population of helper T cells that are latently infected by the wild-type HIV strain or mutated
HIV strain, but when active will replicate mutated virions. With mutation present in the
system, we must account for the population of mutated HIV free virions, denoted Vr, which
infect the healthy helper T cell population. Thus kr is the rate of infection of the helper
T cells by the mutated HIV strain and the term krTVr in (2.1) represents the number of
such infections per unit time. This term then contributes to the actively infected helper T
cells, Ir, and latently infected helper T cells, Lr, populations. Hence, the terms (1−p)krTVr
and pkrTVr appear in equations (2.5) and (2.6). The model also accounts for the event in
which latently infected cells are stimulated to become actively infected for both types of
HIV strains. The parameters αs and αr represent the activation rate of the latently infected
helper T cells that upon activation will produce the wild-type HIV virions or the mutated
HIV virions, respectively. This calculation is reflected in the decrease of the latently infected
helper T cell populations by the terms αsLs and αrLr in equations (2.3) and (2.6) with a
simultaneous increase in the actively infected helper T cell populations in equations (2.2)
and (2.5). The corresponding death rates of latently infected helper T cells and actively
infected helper T cells are included using the parameters dL and dI . The parameters Ns
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and Nr represent the total number of virus particles released by a helper T cell actively
producing wild type virions or mutated virions, respectively, over its lifespan. Finally, the
parameter dV accounts for the clearance rate of free virions. We assume that both the wild
type HIV strain and the mutated HIV strain have the same clearance rate. A summary of
all parameters and their values is given in Table 2.1.
Table 2.1 Variables and Parameters
Initial values References
Dependent variables / Populations
T Uninfected CD4+ T cells 106 ml−1 [9, 10]
Is CD4
+ T cells actively infected producing wild-type virions 0
Ls CD4
+ T cells latently infected will produce wild-type viri-
ons
0
Vs Wild-type HIV virions 10
−6 ml−1 [11]
Ir CD4




+ T cells latently infected will produce mutated/drug-
resistant virions
0
Vr Mutated/Drug-resistant HIV virions 0
Parameters and constants
λ Rate of supply of immunocompetent CD4+ T cells 104 ml−1 day−1 [6]
dT Death rate of uninfected CD4
+ T cells 0.01 day−1 [12]
ks Infection rate of CD4
+ T cells by wild-type HIV virions 2.4×10−8 ml day−1 [11]
kr Infection rate of CD4
+ T cells by mutated/drug-resistant
HIV virions
2.0×10−8 ml day−1 [6]
p Portion of latently infected CD4+ T cell population 0.1 [13]
dI Death rate of actively infected CD4
+ T cell population 1 day−1 [14]
dL Death rate of latently infected CD4
+ T cell population 4× 10−3 day−1 [13]
αs Activation rate for latently infected CD4
+ T cells of wild-
type HIV strain
0.01 [13]
αr Activation rate for latently infected CD4
+ T cells of
mutated/drug-resistant HIV strain
0.01 [13]
Ns Burst size of wild-type HIV virus 3000 [15–17]
Nr Burst size of mutated/drug-resistant HIV virus 2000 [6]
µ Mutation rate from wild-type HIV virus to mutated/drug-
resistant HIV virus
3× 10−5 [18]
dV Clearance rate of free virus 23 day
−1 [19]
Here, Figure 2.1 presents simulation results for the CD4+T cell and viral populations
of both wild-type and mutated strains with parameters from Table 2.1. The initial value
of uninfected helper T cells is T (0) = 106 ml−1 [6]. The initial wild-type viral population,
Vs = 10
−6 ml−1 [6], indicates the strength of the initial infection. All other initial values
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are set to zero as we assume that no infections or mutations have occurred beforehand.
We find in our simulation that both virus populations persist in the body but the steady
state value of the wild-type virus is far greater than that of the mutated virus population. In
Figure 2.1(b), the wild-type population reaches a steady state value of 8.5×105 virions ml−1.
In Figure 2.1(c), the mutated virus population reaches a steady state value of 38.3 virions
ml−1. The healthy CD4+ T cell populations attains a steady state value around 3.2 × 105
virions ml−1 seen in Figure 2.1(a).

























(a) Healthy T cells






















(b) Wild-type HIV Strain






























(c) Mutated HIV Strain



















(d) Total Virus Load
Figure 2.1 A representative simulation of healthy T cells and viral loads of both the wild-
type and mutated HIV strains. Results are presented on log-log scales. Steady state values
for populations not shown here are actively infected helper T cells Is = 6.5× 103 ml−1 and
Ir = 0.44 ml
−1 and latently infected helper T cells Ls = 4.8 × 104 ml−1 and Lr = 3.24
ml−1. Notice that the wild-type viral strain seems to dominate as its steady state value is
five orders of magnitude larger than the mutated strain. [20] found evidence showing the
mutant strain has loss of fitness compared to the wild-type strain.
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2.4 Mathematical Analysis
After constructing the model, we want to be certain that solutions exist and they are
unique. We are able to show local existence using the Picard-Lindelöf Theorem. We would
then want to extend this local existence to global existence. The proof of global existence
would require other rigorous methods which will not be considered here. Instead, existence
and uniqueness globally is assumed once local existence and uniqueness has been established.
2.4.1 Existence and Uniqueness
The Picard-Lindelöf Theorem states that for the initial value problem y′(t) = f(y(t)),
y(t0) = y0, t ∈ [t0− ε, t0+ ε], if f is locally Lipschitz in y and continuous in t, then for some
value ε > 0, there exists a unique solution y(t) to the initial value problem within the range
[t0 − ε, t0 + ε].
To apply this theorem to the model, we must show that indeed f(y) := RHS (2.1) - (2.7),
where y is a vector whose components are T, Is, Ls, Vs, Ir, Lr, Vr, is locally Lipschitz contin-
















−dT − krVr − ksVs 0 0 −Tks 0 0 −Tkr
(1− µ)(1− p)ksVs −dI αs (1− µ)(1− p)Tks 0 0 0
(1− µ)pksVs 0 −dL − αs (1− µ)pTks 0 0 0
0 dINs 0 −dV 0 0 0
(1− p)krVr + µ(1− p)ksVs 0 0 µ(1− p)Tks −dI αr (1− p)Tkr
pkrVr + µpksVs 0 0 µpTks 0 −dL − αr pTkr















is linear in y. Thus, ∇f(y) is continuous on a closed interval and differentiable on an open
interval I. By the Mean Value Theorem, we know |f(y1)−f(y2)||y1−y2| ≤ |∇f(y
∗)| for some y∗ ∈ I.
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By letting |∇f(y∗)| = K, we obtain |f(y1) − f(y2)| ≤ K|y1 − y2| for all y1, y2 ∈ I. Thus,
f(y) is locally Lipschitz. Moreover by Picard-Lindelöf, the system has a unique solution
for some ε > 0 on the interval [t0 − ε, t0 + ε]. With the assurance of local existence and
uniqueness confirmed, we can now press on to examine the behavior of the system.
2.4.2 Steady States
To discuss the long term behavior of the solutions to (2.1) - (2.7), we examine equilibrium
points or steady states, i.e., values of y = [T, Is, Ls, Vs, Ir, Lr, Vr]T , where the rate of change
is constant. These steady states are indicators of the behavior of solutions for large time. We
want to determine the stability properties of each steady state to examine whether solutions
tend toward (stable equilibrium) or away from (unstable equilibrium) these values as t→∞.
A number of long calculations show that there exist exactly three equilibrium points E0, Er













































































































































































where Rr, Rs, Rc, σ and σc are defined by:
Rr =
λkrNr(αr + (1− p)dL)
dTdV (dL + αr)
, Rs =
λksNs(αs + (1− p)dL)
dTdV (dL + αs)
Rc = (1− µ)Rs, σ =
Rs
Rr
, σc = (1− µ)σ.
E0 is the infection free steady state since all populations except T are zero. Er is the steady
state in which only the mutated HIV strain remains present as all populations created by
interaction with the original HIV strain, Is, Ls and Vs, are zero. Thus, Er is called the
mutant dominant steady state. Ec is the equilibrium point in which the two HIV strains
both continue to prevail. Hence, Ec is referred to as the coexistent steady state.
2.4.3 Existence of Steady States
For these steady states to correspond to a physical model, all components must be greater
than or equal to zero for all time. Clearly, this is the case for the infection free steady state,
E0, but it is not so clear for the other two steady states. Since all parameters are positive,
for Er to contain only non-negative populations we require the value of Rr > 1. Similarly,
for all components of Ec to be non-negative for all time, we would require that Rc > 1 and
σc > 1. Note that Rc > 1 is equivalent to Rs >
1
(1−µ) and σc > 1 by definition implies
Rs >
1
(1−µ)Rr . It would also appear that a requirement of σ > 1 would be needed as well,
however if σc > 1 then σ > 1 as µ ∈ [0, 1]. In Figure 2.2, we can see the regions in which
the steady states will be non-negative for all time based on the values of Rr and Rs, which
are calculated using the given parameters. After establishing a parameter regime, in which
steady states correspond to biologically reasonable events, we must determine whether they
are stable or unstable equilibria of the system.
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Figure 2.2 Regions of biologically-relevant existence for steady states in the (Rr,Rs)-plane.
E0 is the infection free steady state, Er represents the mutated strain dominant steady state,
and Ec is the coexistence equilibrium. We note that the region {(Rr, Rs) : Rs > 11−µRr and
Rr > 1} contains all three equilibrium values, while all other regions possess one or two.
2.4.4 Stability of Steady States
Using the Hartman-Grobman Theorem [21] to examine the behavior of solutions with
respect to the steady states in the non-linear system (2.1) - (2.7), and based on our analysis
of the system and numerical simulations we develop the following theorem.
Theorem 2.1. The local stability properties of the equilibria depend only upon the two pa-
rameters Rr and Rs. Moreover,
1. The infection-free steady state E0 is locally asymptotically stable (l.a.s.) if and only if
Rs < 1/(1− µ) and Rr < 1, and it is unstable otherwise.
2. The steady state with only the mutated virus, Er, is l.a.s. if and only if Rs <
1
(1−µ)Rr and Rr > 1, and it is unstable otherwise.
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3. The coexistence steady state Ec is l.a.s. if and only if Rs > 1/(1 − µ) and Rs >
1
(1−µ)Rr, and it is unstable otherwise.
We consider the linearization of the system for each steady state to justify conclusions
about the local asymptotic behavior in the non-linear system. In evaluating the Jacobian at
the infection free steady state, we create the corresponding linear system dy
dt
= ∇f(E0)y. The

























−dT 0 0 −λksdT 0 0 −
λkr
dT
0 −dI αs (p−1)λ(µ−1)ksdT 0 0 0
0 0 −dL − αs −pλ(µ−1)ksdT 0 0 0
0 dINs 0 −dV 0 0 0
0 0 0 − (p−1)λµks
dT
−dI αr − (p−1)λkrdT
0 0 0 pλµks
dT
0 −dL − αr pλkrdT




























2 + a1x+ a0
where
a3 = 1,
a2 = dIdT + dLdT + αrdT + dTdV ,
a1 = dT
2(dV + dI)(dL + αr) + dT
2dV dI − dIdT (1− p)λkrNr,
a0 = dT
3dV dI(dL + αr)− dIdT 2λkrNr(αr + (1− p)dL),
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and λ5,6,7 defined as the roots of the cubic polynomial
a∗3x
3 + a∗2x





a∗2 = dIdT + dLdT + αsdT + dTdV ,
a∗1 = dT
2(dV + dI)(dL + αs) + dT
2dV dI − dIdT (1− µ)(1− p)λksNs,
a∗0 = dT
3dV dI(dL + αs)− dIdT 2(1− µ)λksNs(αs + (1− p)dL).
It follows from the Hartman-Grobman Theorem [21] that the infection free steady state, E0,
is locally asymptotically stable if and only if Re(λi) < 0 for all eigenvalues, λi, of ∇f(E0).
By the Routh-Hurwitz Theorem, the roots of these cubic functions will possess negative
real parts if and only if all coefficients, a3, a2, a1, and a0, are positive and a2a1 > a3a0. We
clearly see that for both cubic functions a3, a
∗
3, a2, and a
∗
2 are positive since all parameters
are positive, but a1, a
∗
1, a0, and a
∗
0 must be examined. For the first cubic, a long calculation
yields
a1 = dT
2(αr + dL)(dI + dV ) + dT
2dIdV [1−Rr + γ] > 0 if only Rr < 1,
a0 = dT
3dV dI(αr + dL)[1−Rr] > 0 if and only if Rr < 1
where γ = Rrαrp
(1−p)dL+αr . Note that a2a1 > a3a0 since
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a2a1 = dT (dI + dV )[dT
3(αr + dL)
2(dI + dV ) + dT
3dIdV (αr + dL)(1−Rr + γ)]
= dT (dI + dV )[dT
3(αr + dL)
2(dI + dV ) + dT
3dIdV (αr + dL)γ + dT
3dIdV (αr + dL)(1−Rr)]
= dT (dI + dV )[dT
3(αr + dL)
2(dI + dV ) + dT
3dIdV (αr + dL)γ + a0]
and all parameters are positive. For the second cubic, we find
a∗1 = dT
2(dI + dV )(αs + dL) + dT
2dIdV [1− (1− µ)Rs + ξ] > 0 if only (1− µ)Rs < 1
a∗0 = dT
3dV dI(αs + dL)[1− (1− µ)Rs] > 0 if and only if (1− µ)Rs < 1
where ξ = (1−µ)Rspαs











1 = dT (dI + dL + αs + dV )[dT
2(dI + dV )(αs + dL) + dT
2dIdV (1− (1− µ)Rs + ξ)]
= (dI + dL + αs + dV )[dT
3(dI + dV )(αs + dL) + dT
3dIdV ξ + dT
3dIdV (1− (1− µ)Rs)]
= (dI + dL + αs + dV )[dT
3(dI + dV )(αs + dL) + dT
3dIdV ξ + a
∗
0]
and all parameters are positive.





be positive for the second cubic if and only if Rs <
1
1−µ . We conclude that E0 is a locally
asymptotically stable steady state for these particular Rr and Rs values. A similar analysis
is used to prove the second and third conclusions of the theorem. The details are omitted
but a computational approach validates the theorem.
In Figure 2.2, there are three regions containing two or more steady states. In the area
of the (Rr, Rs)- plane where Rs >
1
1−µ and Rr < 1 (Region 1), both E0 and Ec exist. For
Rs >
1
1−µRr and Rr > 1 (Region 2), all three steady states, E0, Er and Ec, exist. For
Rs <
1
1−µRr and Rr > 1 (Region 3), both E0 and Er exist.
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(a) T (t) behavior for Region 1 (b) T (t) behavior for Region 2 (c) T (t) behavior for Region 3
Figure 2.3 Stability of Equilibrium points in various regions of the (Rr, Rs)-plane. In fig-
ure (a) (Rr, Rs) = (0.5631, 1.5205), while for (b) (Rr, Rs) = (1.6894, 2.2808), and for (c)
(Rr, Rs) = (2.1962, 1.5205). In each figure, the green line (dotted) represents the population
of healthy T cells in the infection free steady state, E0, the red line (dashed) represents
the population of healthy T cells in the mutation dominant steady state, Er, the blue line
(dot-dashed) represents the population of healthy T cells in the coexistent steady state, Ec,
and the black curve (solid) is the solution T (t) with T (0) = 106.
Computer simulations show the stability of these coexisting steady states. The results of
the healthy T cell population, T (t), are displayed. The simulations begin with parameters
such that the value of (Rr, Rs) is in Region 1, where E0 and Ec exist. In Figure 2.3(a) with
these fixed parameters values, the healthy T cell population, T (t), (black/solid) tends to the
corresponding coexistent steady state value of Ec (blue/dot-dashed). Similarly, adjusting
the parameters so that the value of (Rr, Rs) lies in Region 2, where all three steady states
exist, the healthy T cell population again tends to the corresponding coexistent steady state
population value which is observed in Figure 2.3(b). Thus, we conclude in Region 1 and
2 of the (Rr, Rs) - plane that the coexistent steady state, Ec, is stable while E0 and Er
are unstable. Once again using different parameter values to obtain an (Rr, Rs) value in
Region 3, the population of healthy T cells tends to the corresponding T component value
of the mutant dominate steady state, Er, (red/dashed) as t→∞ in Figure 2.3(c). Thus in
Region 3, the mutant dominant steady state, Er, is the stable. While only the healthy T
cell population is presented, all other populations, Is, Ls, Vs, Ir, Lr, and Vr display the same
long term behavior in the simulations. Additionally, beginning close to the other steady
states displays their instability. Figure 2.4 summarizes these findings.
16
Figure 2.4 Regions of stability of equilibrium points in the (Rr,Rs)-plane
2.5 Drug Therapy
In the previous section, the long term behavior of populations was shown to depend
crucially upon parameter values. Even in the presence of viral mutation, it is possible for the
virus to be completely cleared from the body. The mutated strain, however, may dominate
the dynamics, which can lead to drug resistance. Next, the introduction of Antiretroviral
(ARV) drugs is considered. These drugs hinder different stages of viral replication in an
infected CD4+ T cell. Well known ARV drugs are protease inhibitors which cause infected
cells to produce immature virus particles that are noninfectious and entry/fusion inhibitors
which prevent the virus from entering a healthy T cell. We introduce another type of
drug, reverse transcriptase inhibitors (RTIs), into the model. RTIs attach to the reverse
transcriptase enzyme and prevent it from converting RNA to DNA thus altering the rates
of infection, ks and kr, for the respective HIV strains.
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2.5.1 The Model with Antiretroviral Therapy
Let εs represent the efficacy rate of the RTI drug on the wild-type HIV strain. We assume
the drug is given to combat the wild-type strain and the mutation present in the system is
more resistant to the drugs. Hence, our mutated virions will also be referred to as drug-
resistant virions. The drug-resistant HIV strain can be effected by the introduction of drug
therapy but to a lesser extent. The efficacy of the RTI drug on the drug-resistant strain is
denoted εr. We define εr = αεs, where α ∈ (0, 1) and represents the reduction in efficacy due
to the mutation of the drug-resistant HIV strain. For smaller values of α the drug therapy
is less effective on the drug-resistant strain. In the following analysis, the efficacy rates
εs, εr ∈ (0, 1) are assumed constant with respect to time, though a time-dependent analysis
could also be performed [6]. The introduction of this therapy to our previously examined
model leads to the following equations:
dT
dt
= λ− dTT − (1− εs)ksTVs − (1− εr)krTVr (2.8)
dIs
dt
= (1− p)(1− µ)(1− εs)ksTVs + αsLs − dIIs (2.9)
dLs
dt
= p(1− µ)(1− εs)ksTVs − αsLs − dLLs (2.10)
dVs
dt
= NsdIIs − dV Vs (2.11)
dIr
dt
= (1− p)µ(1− εs)ksTVs + (1− p)(1− εr)krTVr + αrLr − dIIr (2.12)
dLr
dt
= pµ(1− εs)ksTVs + p(1− εr)krTVr − αrLr − dLLr (2.13)
dVr
dt
= NrdIIr − dV Vr . (2.14)
We see that the model which includes drug therapy does not differ much from the model in
Section 2.3. Since the introduction of RTIs effect the parameter values ks and kr, (1− εs)ks
and (1 − εr)kr account for the influence of drug therapy in inhibiting the rate of infection.
In fact, the steady states are nearly identical to those found in the previous model except
18






















































































































































































ε and σεc are defined by:
Rεr = (1− εr)Rr, Rεs = (1− εs)Rs,
Rεc = (1− µ)Rεs, σε =
Rεs
Rεr
and σεc = (1− µ)σε.
We again have an infection free steady state, E0
ε, a drug-resistant dominant steady state,
Er
ε, and a coexistent steady state, Ec
ε. The analysis of existence of solutions and stability of
these steady states adhere to the same conclusions as with the previous model when letting
Rr = R
ε
r, Rs = R
ε
s, Rc = R
ε
c, σc = σ
ε
c and σ = σ
ε. Figure 2.5 displays Theorem 2.1 applied
to the model with antiretroviral drug therapy.










c . Taking into account all possible drug strengths against a known mutation
rate, the values, ε1 and ε2, are the threshold values for which the long term behavior of
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Figure 2.5 Regions of stability of equilibrium points obtained from the antiretroviral therapy
model in the (Rεr,R
ε
s)-plane. E0
ε is a stable steady state when Rεc < 1 and R
ε
r < 1. Er
ε is a
stable steady state when Rεr > 1 and σ
ε
c < 1. Ec
ε is a stable steady state when Rεc > 1 and
σεc > 1
solutions changes.
For values of εs < ε1, Figure 2.6 shows R
ε
r > 1, R
ε
c > 1 and σ
ε
c > 1. Theorem 1
concludes the populations tend toward the coexistent steady state, Ec
ε, with the wild-type
virus population dominating the drug-resistant population. The efficacy of the drug is too
weak to eradicate the virus of either strain. When εs = ε1 this implies σ
ε
c = 1, and hence
our restrictions for the coexistent steady state are no longer met and the long term behavior
of the populations change. For ε1 < εs < ε2, R
ε
r > 1 and σ
ε
c < 1, thus the populations tend
toward the drug-resistant dominant steady state, Er
ε, by Theorem 1. The drug is effective
enough to combat the wild-type strain to below detectable levels but the drug-resistant strain
thrives since it can withstand the treatment. It is not until εs > ε2, implying R
ε
r < 1 and
σεc < 1, that the efficacy rate is strong enough to eliminate the mutated strain. Thus, when
α = 0.5, clearance can be obtained with an efficacy rate εs ≥ ε2 ≈ 0.8162.
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Figure 2.6 With α = 0.5, we obtain threshold values of ε1 ≈ 0.6154 and ε2 ≈ 0.8162.
We investigate the change in the long term behavior of each viral load by graphing the
steady state values of Vr and Vs separately against εs. Figure 2.7(a) and Figure 2.7(b) show
the change in the steady state of the drug resistant virus population. For Figure 2.7(a), the
entire range of efficacies is visible. It demonstrates the dramatic increase in steady state
values of the drug-resistant population near εs = ε1, but cannot display the increase in
population for values of εs < ε1. Thus, Figure 2.7(b), an enlargement of ??(a), shows the
slow, smooth increase in the steady state value of the drug resistant virus population. Fig-
ure 2.7(a) shows the drug-resistant population rapidly declining for εs > ε1 as εs approaches
ε2 and dying out when εs = 1. In Figure 2.7(c), we note the steady decline in the equilibrium
of the wild-type virus population as εs increases and the extinction of the population when
εs = ε1. Figure 2.7(d) provides the total virus population.
Fixing α at a lower value, we discover the change in the dynamics with a more resistant
mutant strain present. The steady state behavior of the viral loads is examined in Figure 2.8.




c , are graphed against varying values
of εs with a resistance level of α = 0.2. We see in Figure 2.8, the threshold ε1 = 0.5 marks
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(a) Steady state of Vr for all values of εs

























(b) Steady state of Vr for εs < ε1





















(c) Steady state of Vs



























(d) Steady state of total virus
Figure 2.7 Dynamics of the steady state values for both the wild-type virus population and
the drug-resistant virus population with respect to εs, the efficacy rate, assuming α = 0.5.
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when σεc = 1 and indicates the shift from a coexistent steady state to drug-resistant dominant
steady state. There is no longer a threshold of ε2 signaling the drug efficacy, εs, could never
be physically large enough to counter the resistance level and eliminate the drug-resistant
strain. Thus, the infection would persist unless another drug is introduced.
Figure 2.8 With α = 0.2, we obtain a threshold value of ε1 ≈ 0.5
The graphs of the steady state values Vr and Vs against εs reveal the long term behavior of
each viral load. Figure 2.9 documents the change in the wild-type and the drug-resistant virus
populations assuming α = 0.2. In Figure 2.9(a), the spike in the drug-resistant population
steady state occurs again at εs = ε1, but unlike Figure 2.7(a) the population remains large
when εs = 1. An enlargement of the drug-resistant population curve shows the minimal
but steady growth of this strain for εs < ε1, see Figure 2.9(b). Figure 2.9(c), as compared
to Figure 2.7(c), demonstrates the faster decline in the steady state of the wild-type virus
population as εs → 1 and the earlier extinction of this population when εs = ε1. Figure 2.9(d)
provides the total virus population, exhibiting viral clearance is no longer attainable as the
total population remains above zero when εs = 1.
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(a) Steady state of Vr for all values of εs


























(b) Steady state of Vr for εs < ε1

























(c) Steady state of Vs
























(d) Steady state of total virus
Figure 2.9 Dynamics of the steady state values for both the wild type virus population and
the drug resistant virus population with respect to εs, the efficacy rate, assuming α = 0.2.
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Simulations test the previous conclusions about the dynamics of this system for α = 0.2
while holding εs = 0.4. With εs < ε1 ≈ 0.5, we predict the populations to reach a coexistent
steady state with a wild-type viral population dominance. Figure 2.10 displays the results.
Figure 2.10(b) and Figure 2.10(c) confirm our predictions and show a steady state value of
the wild-type virus to be 572, 499 virions ml−1 and a steady state value of 77.3 virions ml−1
for the drug-resistant virus. The healthy CD4+ T cell population reaches a steady state of
548, 083 cells ml−1 in Figure 2.10(a). The populations, in Figure 2.10, display a damped
oscillatory pattern due to the inclusion of latent infection in the model. This is in contrast
to the oscillatory behavior of these populations with the same values for εs and α in the
model without latent infection [6].


























(a) Healthy T cell population































(b) Wild-type virus population






























(c) Drug-resistant virus population




























(d) Total virus population
Figure 2.10 Assuming εs = 0.4 and α = 0.2, using parameter values found in Table 2.1 we
have the time evolution of the uninfected CD4+ T cells, the wild type and drug resistant
virus populations.
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In changing εs = 0.54, we predict, based on Figure 2.8, the populations T , Vs, and Vr
would maintain a drug-resistant dominant steady state. Simulations justify these conclusions
in Figure 2.11. In Figure 2.11(b), the wild-type virus population tends toward extinction
while in Figure 2.11(c), the drug-resistant virus population reaches a steady state value of
266, 744 virions ml−1. We observe, in Figure 2.11(a), the healthy CD4+ T cell population
reaches a steady state value of 666, 530 cells ml−1. Again, due to the presence of latent
infection, all populations exhibit a damped oscillatory behavior as compared to the behavior
of these populations in the model without latent infection [6].























(a) Healthy T cell population


























(b) Wild-type virus population






























(c) Drug-resistant virus population
























(d) Total virus population
Figure 2.11 Assuming εs = 0.54 and α = 0.2, using parameter values found in Table 2.1 we
have the time evolution of the uninfected CD4+ T cells, the wild type and drug-resistant
virus populations.
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We question whether stronger drugs, i.e. higher values of εs, will have a significant
effect on a drug-resistant population with a mutation so resistant that the drug is only
20% effective. The results of greater efficacy rates on the healthy CD4+ T cell population
and the drug-resistant virus population appear in Figure 2.12. For larger values of εs,
still holding α = 0.2, we see only a relatively small increase in the healthy CD4+ T cell
population from 672, 714 cells ml−1 when εs = 0.6 to 704, 664 cells ml
−1 when εs = 0.8.
There is an insignificant decrease in the drug-resistant population from 276, 345 virions ml−1
to 249, 479 virions ml−1 with increasing efficacy rates, indicating the obstinacy of a mutant
viral population of high resistance.


























































Figure 2.12 Dynamics of healthy CD4+ T cell population and drug-resistant virus population
with εs = 0.6 and εs = 0.8 assuming a resistance level α = 0.2.
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Figure 2.13 summarizes the relation between varying resistance levels of mutations and
strength of drug efficacies and their role in determining the long term behavior of the various
populations. The regions of stability from Figure 2.4 are plotted in the (εs, α)-plane to gain
the greatest insight into this correspondence. Assuming we begin with a coexistent steady
state prior to drug therapy, three scenarios arise given various α and εs values. The first
involves a weak mutation. We define weak to imply the effect of the drug on the mutant





(1−µ)Rs−1). Introducing a drug with
εs > 1− 1(1−µ)Rs ⇐⇒ R
ε
c < 1 leads to clearance of both viral strains. The thresholds of drug
effecacies, ε1 and ε2, appear when the mutation produces a stronger resistance to drugs, i.e.
αmin < α < αmax. Recall ε1 appeared when εs was high enough that σ
ε





) and ε2 appeared when εs was high enough that R
ε




We discovered this situation in the example when α = 0.5 and we found ε1 = 0.6154 and
ε2 = 0.8162. Hence, viral clearance can be obtained assuming a drug is effective enough.
The third situation, however, produces a threshold of viral persistence, αmin = 1 − 1Rr . In
this scenario, the mutant produced is so strong, i.e. α < αmin that only the clearance of the
wild-type strain can be obtained when εs > 1 − Rr(1−µ)Rs . An example of this was studied
previously when α = 0.2 and ε1 = 0.5.
Beginning from a mutant dominant steady state prior to drug therapy produces a similar
scenarios of the second and third type only. The coexistent steady state region no longer
appears in the (α, ε)-plane for this case.
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Figure 2.13 Regions of stability based on the efficacy, εs, of the RTI and levels of resistance,
α, of the mutated HIV strain.
2.6 Sensitivity Analysis
The system (2.1)-(2.7) yielded insights into the long term outcome of population size
based on initial parameter values. We see the characteristic oscillatory behavior, however,
damped with the introduction on latent infection, in T cell count and viral load within the
first stage of infection. We investigated the relationship between drug efficacy and resistance
due to mutation in (2.8)-(2.14). In this section, we will look into a more precise correlation
between parameter values and population size, hoping to discover which parameters have the
greatest effect on population sizes at given time t. We began with choosing our population
of interest to be healthy T cell count. We perform a parameter sweep of this population by
fixing twelve of the thirteen parameter values and varying one parameter across a biologically
realistic range, typically ±10% of the baseline value found in Table 2.1. A sample of these
results is given in Figure 2.14 where the T cell count, at t = 650 days, is calculated for
varying values λ, ks, Ns, and dV . There is an apparent linear relationship between the
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healthy T cell count and the supply, infection and clearance rates. While Figure 2.14(c)
signals a quadratic relation for the burst rate and healthy T cell count. Perhaps the most
important characteristic to notice within Figure 2.14 is the monotonic relation between the
healthy T cell count and each parameter; indicating the possible existence of a global linear
model in which to obtain an active subspace of the parameter space [22].
(a) supply rate (b) infection rate
(c) burst rate (d) clearance rate
Figure 2.14 Parameter Sweeps
To construct a global linear model, we assume that the healthy T cell count at a fixed time
t, can be estimated using T̂t(xi) = a0 + a1x1 + ... + a13x13 where xi = [xi,1, xi,2, ..., xi,13]
T =
[λ, ks, kr, p, µ, αr, αs, Ns, Nr, dT , dI , dL, dV ]
T which are obtained from the ith random draw
(uniformly distributed) from the ranges of the parameter space used in the parameter sweeps
and a0, a1, a2, ..., a13 are real valued coefficients. Let
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where N is the finite number of random draws for which the healthy T cell count was
calculated at t days. To obtain the T̂t(x) which is the closest approximation to Tt(x), we
need to find the minimum of φ(a0, a1, ...a13), i.e., find a0, a1, ...a13 such that the derivative
∂φ
∂ai




































































































































































































































































Hence, a is the least squares solution of A x = b. Therefore, our global linear approximation
T̂t(x) can be found by generating matrix A and vector b and solving for the least squares
solution, a. By redefining T̂t(x) = a0 + w
Tx, where w = [a1, a2, ...a13]
T , we calculate
∇T̂t(x) = w. Thus, we are actually finding a one dimensional active subspace.
An active subspace is derived from the gradient of Tt(x), using the average of the outer
product of the gradient with itself, denoted C =
∫
∇Tt(x)∇Tt(x)Tρ dx, where ρ is a normal
density function. The active subspace finds a set of directions in the parameter space which
directly impact the rate of change of the healthy T cell count. We, however, have estimated




wwTρ dx = wwT
∫





T . This eigenvalue decomposition leads to a one dimensional active
subspace which is referred to as the active variable vector. The components of this eigenvector
are weights for each parameter’s effects on the amount of healthy T cells at a particular time
t. A true active subspace will likely be more than one dimension but the power of the
global linear model is apparent when used with a sufficient summary plot (SSP) [22]. A SSP
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correlates the quantity of interest, the T cell count at time t, with a linear combination of the
input parameters, y = wTxi for i = 1, ..., N . Essentially the SSP appears as a scatter plot.
However, we are able to obtain a continuous function by means of a nonlinear fit to calculate
the T cell count at time t using the fitted function evaluated with the linear combination of
input parameters in lieu of solving a system of ODEs.
2.6.1 Numerical Results
Select N = αm where m is the number of input parameters and α is an oversampling fac-
tor. A rule of thumb in random sample algorithms is to set 2 < α < 10 [22]. However, with
the cost of this simulation being relatively low, we take N = 500. We fixed t = 650 which
indicates long time in both (2.1)-(2.7) and (2.8)-(2.14). In Figure 2.15(b), we see the SSP of
the T cell count. We calculate a quadratic relation using a nonlinear model fit and approxi-
mate T (650) with T̂650(y) = D0 +D1y +D2y
2. Hence, our quantity of interest, T (650), can
be calculated based on the chosen input parameters, x, and our corresponding active vari-
able vector, w. Thus, the cost of finding T (650) has drastically decreased. Calculations for
T (650) can be further simplified by approximating w with w̃ = [0, a2, 0, ..., 0, a8, 0, ..., 0, a13].
This particular vector, w̃, is chosen based on the close proximity of entries in the active
variable vector, w, to zero as displayed in Figure 2.15(a).
Further justification for the approximation of w comes from the calculated error between
the active variable vector and the reduced active variable vector. Note that the error =
||wwT −w̃w̃T ||2 ≈ .06. From the L2-norm, we see that the largest singular value is relatively
small. The difference between the span of the active variable vector and the reduced vector,
both normalized vectors, is approximately 6%.
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(a) Active Variable Vector for t = 650 days (b) Sufficient Summary Plot for t = 650 days
Figure 2.15 we obtain a reduced quadratic model for estimating the healthy T cell count at
650 days: g(y) = 330780 + 120909y + 27775.7y2 where y = wTxi. Based on the weights of
w we can further simplify calculations by approximating y ≈ a2x2 + a8x8 + a13x13.
Initial numerical results were calculated for a specific time, t = 650 days. The next step
is to vary the time for which we want to calculate the quantity of interest from 100 to 1200
days in intervals of 100. In Figure 2.16, the corresponding active variable vectors and the
fitted quadratic model of each sufficient summary plot have been overlaid to emphasize the
similarities of the results.
(a) Active Variable Vector (b) Best Fit Function
Figure 2.16 The active variable vector w varies slightly for some entries, however, the
same approximation vector w̃ = [0, a2, 0, ..., 0, a8, 0, ..., 0, a13] can be used for calculating
the healthy T cell count for t ≥ 100. Similarly, the fitted quadratic model, T̂t(y) =
D0 + D1y + D2y
2, has varying coefficients but a single function could be chosen to con-
fidently estimate the healthy T cell count for t ≥ 100 days with a low cost calculation. See
Table 2.2 for exact results.
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Table 2.2 Best Fit Functions for Sufficient Summary Plots in Figure 2.16
Time Model
100 330573 + 117900y + 20712.9y2
200 332186 + 117766y + 21081.1y2
300 332637 + 117772y + 21093.8y2
400 332708 + 117693y + 21091.1y2
500 332701 + 117633y + 21092.3y2
600 332684 + 117592y + 21093.8y2
700 332667 + 117561y + 21094.4y2
800 332651 + 117537y + 21094.9y2
900 332638 + 117517y + 21095.9y2
1000 332627 + 117502y + 21097.5y2
1100 332618 + 117491y + 21099y2
1200 332612 + 117483y + 21100.2y2
The results of obtaining the global linear approximation are not so similar for t ≤ 100
days. The active variable vector varies between 0 ≤ t ≤ 100. More significantly, the
obtained fitted function varies greatly within this time range. Figure 2.17 displays the
various active variable vectors with corresponding best fit functions to the sufficient sum-
mary plots for 0 ≤ t ≤ 100. There are three distinct approximating active variable
vector: w̃1 = [a1, 0, ..., 0, a10, 0, ..., 0] (Figure 2.17(a)), w̃2 = [0, a2, 0, ..., 0, a8, 0, ..., 0, a13]
(Figure 2.17(c) and (g)), and w̃3 = [a1, a2, 0, ..., 0, a8, 0, ..., 0, a11, 0, a13] (Figure 2.17(e)).
We incorporate all significant parameter values into one reduced active variable vector
w̃ = [a1, a2, 0, ..., 0, a8, 0, a10, a11, 0, a13] thus decreasing the number of needed parameters
from 13 to 6. The difference between the span of all active variable vectors and the span
of our chosen reduced active variable vector ranges between .001 and .5, with the greatest
error occurring at 45 days.
Based on the sufficient summary plots in Figure 2.17, we obtain the following piecewise
function for calculating the healthy T cell count at time t = 5n, 1 ≤ n ≤ 18:
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(a) Active Variable Vector for t =
5,10 days
(b) Sufficient Summary Plot
(c) Active Variable Vector for t =
15, 20, 25, 30, 35 days
(d) Sufficient Summary Plot
(e) Active Variable Vector for t =
45, 50, 55, 60, 65, 70 days
(f) Sufficient Summary Plot
(g) Active Variable Vector for t =
75, 80, 85, 90, 95 days
(h) Sufficient Summary Plot
Figure 2.17 Within each subfigure, the days follow the order of the rainbow with red cor-
responding to the earliest day through blue or purple corresponding to the latest day. All
graphs correlate the healthy T cell count at time t with a linear combination of input pa-
rameters, y = wTx. See Table 2.3 for specific details.
36
Table 2.3 Best Fit Functions for Sufficient Summary Plots in Figure 2.17
Reference Time Model
(a)− (b) 5 1× 106 + 6896.86y
(a)− (b) 10 999384 + 13657.5y
(c)− (d) 15 51785 + 336761 tan−1(5.34571 + 9.37124y)
(c)− (d) 20 535458− 329625 tan−1(0.116552− 10.1175y)
(c)− (d) 25 560590− 317152 tan−1(4.55402− 10.9656y)
(c)− (d) 30 547206− 276136 tan−1(9.21345− 14.6643y)
(c)− (d) 35 549960− 246632 tan−1(13.7343− 15.6153y)
(e)− (f) 45 249300 + 42720.6y
(e)− (f) 50 269413 + 30155.3y
(e)− (f) 55 289036 + 35853.0y
(e)− (f) 60 304598 + 50404.8y
(e)− (f) 65 315624 + 67855.4y
(e)− (f) 70 323207 + 84349.6y
(g)− (h) 75 328512 + 97743.4y
(g)− (h) 80 332325 + 107479y
(g)− (h) 85 331284 + 113696y + 10395.5y2
(g)− (h) 90 330149 + 117533y + 18702.4y2






































2 for t = 75, 80, 85, 90, 95.
(2.15)
The model consists of four large variations in the parameter space, with each corresponding
to a portion of the stages of infection. The first linear model captures the healthy T cell
count prior to the infection taking hold. The inverse tangent functions display the infection
dynamics and viral proliferation. The second linear model reflects the asymptomatic/latency
period of the infection. The quadratic model yields values of healthy T cells as the population
tends to equilibrium since the third defined stage of the HIV time course is not represented
by (2.1) - (2.7).
Using initial values and parameters from Table 2.1, we compare the healthy T cell count
given by T̂t(y) in equation (2.15), where y = w̃
Tx, with the corresponding values from
the continuous solution to (2.1) along with the entire solution for 0 ≤ t ≤ 95 days, see
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Figure 2.18. The average of the relative error between the healthy T cell count from T̂t(y)
and the continuous solution for t = 5n, 1 ≤ n ≤ 18 was 0.037 with a maximum relative error
of 0.23 occurring on day 25. Options for obtaining a better approximation would be creating
a finer mesh, i.e., smaller spacing of grid points in time or using higher-order piecewise
interpolants such as cubic splines or piecewise cubic interpolation.
Figure 2.18 The orange graph indicates the healthy T cell count calculated using T̂t(y). The
blue graph is the corresponding times evaluated with the continuous solution obtain through
an implicit Runge-Kutta method in Mathematica as well an the entire continuous solution
in purple.
2.7 Conclusion
Upon formulating a new in-host model of HIV dynamics that incorporates latent infec-
tion and viral mutation, the local asymptotic behavior of the model was characterized and
validated using computational means. The effects of RTIs were elucidated under differing
drug resistance levels for the mutated strain. In particular, our analysis determined that
a sufficiently high resistance level arising from viral mutation could render a persistent in-
fection untreatable. This implies that RTIs alone are not strong enough to counteract the
emergence of drug resistant strains. Additionally, as HIV possesses a strong propensity to
mutate, due to common errors in reverse transcription, the effects of viral mutation are
38
significant within the dynamics of the virus.
Our sensitivity analysis indicates that the parameters which drive the spread of HIV
within CD4+T cells varies with transition between clinical stages of the disease progression.
In the early onset of the disease, the parameters which contribute most significantly to the
sizes of the total populations of interest are the rate of supply of immunocompetent CD4+T
cells and the rate at which uninfected CD4+T cells die. Toward the end of the acute stage,
the infection rate of CD4+ T cells by wild-type HIV virions, the burst size of these virions
and the clearance rate of these virions have the largest effect on the dynamics of the system.
Transition to the second stage or chronic HIV infection stage maintains the parameters from
the previous stage while including the rate of supply of healthy T cells and the death rate
of infected T cells as contributing factors in the active variable vector. It is not until time
has progressed to later in the chronic stage that the active variable vector indicates for the
duration of this stage (7-10 years when gone untreated) the significant parameters in the
dynamics of this system to be the infection rate of CD4+ T cells by wild-type HIV virions,
the burst size of these virions and the clearance rate of these virions.
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CHAPTER 3
BISTABLE DYNAMICS AND HOPF BIFURCATION IN A MODIFIED HIV
INFECTION MODEL
Modified from a paper to be submitted to Applied Mathematics and Computation.
Deborah P. Shutt3 and Stephen Pankavich4
3.1 Abstract
Recent clinical studies have shown that HIV disease pathogenesis can depend strongly
on many factors at the time of transmission, including the strength of the initial viral load
and the local availability of CD4+T cells. In this chapter, a new within-host model of HIV
infection that incorporates the homeostatic nature of the immune system is formulated and
analyzed. Due to the homestasis of the T population, the influence of initial conditions
on the proliferation of infection is further expatiated. The sensitivity of healthy T cell
and virus populations with respect to parameter variation is also investigated and a local
stability analysis, which displays additional complexity in comparison to previous models, is
conducted. The current study extends previous theoretical and computational work on the
acute stage of the disease and leads to interesting nonlinear dynamics, including bistability
of equilibria and the appearance of a Hopf bifurcation within biologically relevant parameter
regimes.
3.2 Introduction
In this chapter, we formulate a modified predictive model for the acute phase, or first
stage, of infection. This model is a simplification of two models, [2, 7], which predict all three
stages of with-in HIV progression. Previously, a standard infection model was developed [23]
and involved two mutually exclusive end states - viral clearance and viral persistence - the
3Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
4Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
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dynamics of which do not depend on initial conditions. In particular, this model assumes that
the strength of the initial viral load and the magnitude of the healthy T cell count at the time
of transmission have no bearing on the development of a persistent infection. We construct
and analyze the following modified model of the acute stage that introduces a regulatory
mechanism known as homeostatic proliferation of healthy T cells and accounts for the local
dependence of equilibrium states on initial conditions. Upon formulating the model, we
validated it via simulation and sensitivity analysis. Parameters were then fit to clinical data.
We further characterized the local dynamics of both the infected and uninfected equilibria.
An interesting aspect of the model is that equilibrium states can exhibit bistability, that
is, both states can be locally stable within a certain parameter regime. Therefore, stability
depends crucially on variations in the initial viral load and healthy T cell count. Simulations
to identify and characterize the basins of attraction were performed to further examine these
local effects. Finally, we prove the existence of a Hopf bifurcation; a change in stability
properties of the system where complex conjugate eigenvalues of the linearization around
an equilibrium transition from Re(λ) < 0 to Re(λ) > 0, giving rise to oscillations and
instabilities.
3.3 The Model
The proposed reduced phase model of [2, 7] contains three fully-coupled ordinary differ-






)T − kTV − dTT (3.1)
dI
dt
= kTV − dII (3.2)
dV
dt
= pT I − dV V. (3.3)
T denotes the population of healthy helper T cells. An estimated maturity rate of helper
T cells to immunocompetent T cells is represented by the parameter λ. The death rate of
these T cells is denoted dT . V is the wild-type HIV strain population which has an infection
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rate, k. The mass action term kTV gives rise to the infected T cell population, I, that has
a death rate of dI . The parameter pT is the rate of new virus particles being created by the
infected T cell population. This single parameter replaces the term NsdI which also yields
the same quantity but uses the burst size and death rate of the infected T cell population
to calculate the contribution. The clearance rate of free virus particles is dV . The immune
response term is described using ρ and cT to capture homeostatic proliferation: the increase
of mature T cells in the presence of the HIV virus. Both pT and cT were adjusted to obtain
appropriate HIV trajectories with respect to clinical observations in [24] and [4], as examined
in [7], [2]. See Table 3.1 for a complete list of variables and parameters with initial values.
The inclusion of the homeostatic proliferation term, as we will show, has a profound effect
on the dynamics of the three component system [25].
Table 3.1 Variables and Parameters
Initial values References
Dependent variables / Populations
T Uninfected CD4+ T cells 1000 mm−3 [2]
I Infected CD4+ T cells 0 mm−3 [2]
V Wild-type HIV virions 0.01 mm−3 [2]
Parameters and constants
λ Rate of supply of immunocompetent CD4+ T
cells
10 mm−3 day−1 [23]
ρ Logistic proliferation parameter .01 day−1 [2]
cT Logistic proliferation parameter 300 copies mm
−3 [2]
k Infection rate of CD4+ T cells by wild-type HIV
virions
4.5× 10−5 mm3 day−1 [7]
dT Death rate of uninfected CD4
+ T cells 0.01 day−1 [7]
dI Death rate of infected CD4
+ T cell population 0.4 day−1 [23]
pT Rate of viral production by infected CD4
+ T cell 38 virions per cell day−1 [7]
dV Clearance rate of free virus 2.4 day
−1 [7]
3.4 Mathematical Analysis
This following sections examine various mathematical characteristics of Model (3.1) -
(3.3). We first prove the existence and uniqueness of solutions for this system. The steady
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states are identified in Section 3.4.2 followed by a local stability analysis of these steady
states. The existence of a Hopf bifurcation is proven in Section 3.4.4. The final section of
the mathematical analysis provides the numerical results of the Hopf bifurcation.
3.4.1 Existence and Uniqueness
Consider the Jacobian of the system, we denote the right hand side of (3.1)-(3.3) as f(y),


























On the compact set [0, U ]3, where U = max{T, I, V }, many of the partial derivatives are




contain terms which are not linear. Further

























|Ji,j(y)| ≤ C(1 + U).
Since f(y) is defined and continuous with partial derivatives which exist and are continuous
and bounded, f(y) is Lipschitz continuous for y ≥ 0 and thus the solution to the system
(3.1)-(3.3) exists and is unique.
3.4.2 Steady States
In the traditional manner of analysis of ODEs, we find and examine the steady states of
the system (3.1)-(3.3). Steady state values have the form y = [T, I, V ]T . Calculations show



















































































where a, b, and c are defined by
a = k, b = cTk(1−Rm) + dT (1−Ro), c = cTdT (1−Ro)











i represent states of persistent infection.
Since all components represent population size, we impose restrictions on the values for which
these steady states exist. All three populations of Eu will remain non-negative for all time.
However, for both E+i and E
−
i , we are concerned with the infected T cell population, I, and
the virus population, V , remaining real and non-negative. To insure real valued populations,
we impose the restriction:
b2 − 4ac ≥ 0⇐⇒ D2 + (−2cTk − 2ρ)D + (cTk − ρ)2 ≥ 0 where D = dT (1−Ro)
⇐⇒

























D − cTk(1 +
√
Rm)







In the (Rm, Ro)-plane the region denoted by Ro < 1− cT kdT (1+
√
Rm)
2 contains only negative




ensure all populations have real values. In requiring all populations to be non-negative,
other restrictions are needed. The cases to consider are as follows:
Case 1: b < 0
If b < 0⇐⇒ Ro > 1 + cT kdT (1−Rm).
For E+i , −b+
√




b2 − 4ac < b is needed to have non-negative populations. Thus for E−i , an
added requirement is necessary: ac > 0⇐⇒ Ro < 1.
Case 2: b > 0
If b > 0⇐⇒ Ro < 1 + cT kdT (1−Rm).
For E+i we must look at two sub-cases:
(a) if ac > 0⇐⇒ Ro < 1 then −b+
√
b2 − 4ac ≤ 0 and E+i has negative
infected T cell and virus populations.
(b) if ac < 0⇐⇒ Ro > 1 then −b+
√
b2 − 4ac ≥ 0 and E+i has non-negative
infected T cell and virus populations.
For E−i , both the infected T cell and virus population will remain negative for all time.
Thus, the steady state does not exist in this region.
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See Figure 3.1 for a summary of these restrictions.
Figure 3.1 Regions of existence for uninfected steady state, Eu, and infected steady states,
E+i and E
−
i in the (Rm, Ro)-plane.
3.4.3 Local Stability Analysis
With the existence of the uninfected and both infected steady states determined, we
examine the conditions, if any, for which these steady states are locally asymptotically stable.
The Hartman-Grobman Theorem [21] states that near a hyperbolic equilibrium point, (i.e.,
the Jacobian evaluated at an equilibrium point which has only eigenvalues with non-zero




We examine the structure of the linear system near the uninfected steady state, Eu. The




























We obtain the eigenvalues from the characteristic polynomial is η3 + d1η
2 + d2η + d3, where
d1 = dI + dV + dT
d2 = dIdV −
λkpT
dT
+ dT (dI + dV )








−(dI + dV ) +
√
(dI + dV )2 − 4dIdV (1−Ro)
2
η3 =
−(dI + dV )−
√
(dI + dV )2 − 4dIdV (1−Ro)
2
All of the eigenvalues have non-zero real part. Thus, Eu is a hyperbolic equilibrium
point. Note also, η1 and η3 have negative real parts. A closer examination of η2 follows to
show that this eigenvalue will also have negative real part under certain conditions. With
the restriction of Ro < 1, we observe:
0 < Ro < 1
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⇐⇒
0 < 4dIdV (1−Ro) < 4dIdV
⇐⇒
−4dIdV < −4dIdV (1−Ro) < 0
⇐⇒
(dI + dV )
2 − 4dIdV < (dI + dV )2 − 4dIdV (1−Ro) < (dI + dV )2
⇐⇒
(dI − dV )2 < (dI + dV )2 − 4dIdV (1−Ro) < (dI + dV )2
⇐⇒
dI − dV <
√
(dI + dV )2 − 4dIdV (1−Ro) < dI + dV
⇐⇒
η2 = −(dI + dV ) +
√
(dI + dV )2 − 4dIdV (1−Ro) < 0
Therefore, all eigenvalues of the Jacobian evaluated at the uninfected steady state, Eu,
have negative real parts. Hence, our linear system, dy
dt
= ∇f(Eu)y is locally asymptotically
stable if and only if Ro < 1. Moreover, by the Hartman-Grobman Theorem, in the non-linear
system (3.1)-(3.3), Eu is locally asymptotically stable if and only if Ro < 1.
Next, we establish the stability of the infected steady states. We take the Jacobian,
∇f(y), and evaluate it only with the healthy T cell population, T = dIdV
kpT
, of E+i and E
−
i
as this is the same value in both steady states. The associated characteristic equation is
η3 + d1η
2 + d2η + d3 = 0 where
d1 = dI + dV + dTRo
d2 = (dI + dV )dTRo
d3 =
−dIdV V
(cT + V )2
(cT
2k(Rm − 1)− k(V 2 + 2cTV ))
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The Routh-Hurwitz Theorem states the roots of a cubic function will have negative real
parts if and only if all coefficients are positive and the product of the second and third
coefficient is greater than the product of the first and fourth coefficient. Clearly, d0, d1,
d2 > 0 since all parameter values are positive. We only concern ourselves with the sign of
d3 and showing d1d2 > d3. Under the current parameter regime, Figure 3.2(a) shows the
regions in the (Rm, Ro)-plane in which d3 > 0 and d1d2 > d3 for E
+
i . Figure 3.2(b) displays
the region in which both inequalities are satisfied for E−i . Recall from Figure 3.1, in the
(Rm, Ro)-plane the infected steady state is stable when Ro > 1 and b
2 − 4ac > 0. The
region of stability, however, is a subset of the region of existence with borders of Ro = 1,
b2 − 4ac = 0 and d1d2 − d3 = 0. Also in Figure 3.1, E−i only exists where b2 − 4ac > 0 and
Ro < 1. Figure 3.2(b) shows E
−
i is only stable in an area outside of its existence region.
Hence, E−i is an unstable steady state for the (3.1)-(3.3) system. In conclusion, using the
Hartman-Grobman Theorem to examine the behavior of solutions with respect to the steady
states in the non-linear system (3.1)-(3.3), and based on our analysis of the system and
numerical simulations we develop the following theorem.
Theorem 3.2. The local stability properties of the equilibria depend only upon the restric-
tions within the (Rm, Ro) parameter space. Moreover,
1. The infection-free steady state E0 is locally asymptotically stable (l.a.s.) if and only if
Ro < 1 and it is unstable otherwise.
2. The infected steady state, E+i , is l.a.s. if and only if Ro > 1,
[cTk(1−Rm) + dT (1−Ro)]2 > 4kcTdT (1−Ro) and




2k(Rm − 1)− k(V 2 + 2cTV )),
and it is unstable otherwise.
3. The infected steady state E−i is locally asymptotically unstable.
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(a) Stability region of E+
i
(b) Stability region of E−
i
Figure 3.2 Regions of the (Rm, Ro)-plane where the Routh-Hurwitz criteria are satisfied. The
blue region denotes where d1d2 > d3 and the yellow region indicates where d3 > 0. The tan
region is where both inequalities are satisfied and the steady states are stable.
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Thus only the uninfected steady state, Eu, and the infected steady state, E
+
i , are locally
asymptotically stable. We compare these regions of local stability in Figure 3.3. The green
region denotes the area of the (Rm, Ro)-plane where Eu is locally asymptotically stable and
the lighter red region denotes local asymptotic stability for E+i . Interestingly, there is a
small overlap of these two regions in which both steady states are locally asymptotically
stable—the darker red triangular region of the plane. The characteristics of the white region
within Figure 3.3 will be addressed in Section 3.4.4.
Figure 3.3 Regions of stability for the uninfected steady state, Eu, shown in green; the
infected steady state, E+i , shown in light red; the bistable region, shown in dark red.
Within the darker red triangular region, computer simulations locate points of the (Rm, Ro)-
plane where Eu is stable and E
+
i is stable, see Figure 3.4. Location points were obtain by
fixing most parameter values from Table 3.1 with the exception of λ and ρ. We chose to vary
these two parameters since λ only appears in Ro and ρ only appears in Rm. Based on these
results, we pick a finite number of these locations to test the sensitivity to initial conditions
of both the healthy T cell count and the initial viral load, thereby enabling the identification
of basins of attraction. The locations tested can be found in Figure 3.5.
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Figure 3.4 Simulation results of steady state values given the initial conditions and parameter
values from the Table 3.1. Green points indicate solutions tending to the infection free steady
state and red points indicate solutions tending to E+i , the infected steady state for long time.
Figure 3.5 Testing sensitivity to initial conditions of healthy T cells and initial viral load
in specific locations in the (Rm, Ro)-plane; (a) (1.82, 0.9), (b) (4.01, 0.9), (c) (7.0, 0.9),
(d) (2.53, 0.6), (e) (4.01, 0.6), (f) (5.45, 0.6), (g) (4.01, 0.27)
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The results, shown in Figure 3.6, display the basins of attraction for the corresponding
locations obtained from varying λ and ρ values. We notice that locations, nearer to the
b2 − 4ac = 0 curve and in the lower corner of the red triangular region, where Eu is locally
asymptotically stable, have a greater basin of attraction for Eu than those locations on
the right side of the darker red triangular region in the (Rm, Ro)-plane as displayed in
Figure 3.5(a), (d), and (g). The appearance of a strip of persistent infection steady state
values grows larger at locations moving from left to right within this region. We see that the
initial viral load has a small influence on the shape of the strip for various locations as the
width of each strip is not uniform. The initial healthy T cell count has a more pronounced
effect on the long term behavior of populations for parameter values within this region. The
range of the initial healthy T cell count which can alter the long term behavior is within
±25% or less of the standard initial healthy T cell count of an uninfected person.
A person infected with HIV typically has baseline parameter values (see Table 3.1) that
indicate a location in the (Rm, Ro)-plane which lies aboveRo = 1 in the E
+
i stability region. If
a person were to undergo ART, specifically using RTIs, the parameter k, the rate of infection,
would be altered and the parameter location could move into the darker red triangular region.
With the introduction of RTIs comes a drop in healthy T cells counts, and therefore, the
modeled long term behavior of populations could tend toward an uninfected steady state or
a persistent infection steady state. The range of initial healthy T cell values which result in
a persistent infection grows larger in proportion to the closeness of the parameter location
to the right side of the dark red triangular region. The standard accepted value for the
initial healthy T cell count, 1000 cell mm−3 is often within ±10% of these varying ranges.
The result of this weaker basin of attraction supports a justification for the occurrence of a
rebound infection.
3.4.4 Hopf Bifurcation
Within the region of existence for the infected steady state, we use ρ, a homeostatic
proliferation parameter, to show the existence of a Hopf bifurcation. Note that ρ ∈ (0,∞) but
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(d) Eu stable (e) Eu stable (f) Eu stable
(g) Eu stable
Figure 3.6 The original initial values are 1000 cells/mm3 of healthy T cells and .01
virions/mm3 for the viral load. Both quantities were changed by ±25%. The green points
indicate where populations tended toward the uninfected steady state and red points indicate
initial conditions in which populations tending toward an infected steady state.
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1)2) so that Ro > 1− cT kdT (1−
√
Rm)
2. Thus, all values remain within the region of existence





































Note the value of b is redefined to emphasize its dependence on ρ as
b(ρ) = cTk − ρ+ dT (1−Ro).
The characteristic polynomial is η3 + d1η
2 + d2η + d3(ρ) = 0 where
d1 = dI + dV + dTRo











b(ρ)2 − 4ac+ cTk + ρ− dT (1−Ro))2
− 1
)
Recall that within the region of existence of E+i , the infected steady state, d3(ρ) > 0.
See Figure 3.1 and the yellow region in Figure 3.2(a) for a visualization of d3(ρ) > 0. We
denote ηi(ρ), i = 1, 2, 3 as the corresponding eigenvalues of the characteristic polynomial.
The mapping from ρ → ηi(ρ) is smooth and continuous as in Figure 3.7 (see [26], Chapter
2). Preliminary observations proven in Lemma 3.1 & 3.2 will provide justification for the
statement of existence of a Hopf Bifurcation in Theorem 3.3.
Lemma 3.1. For fixed ρ, in the region of existence for E+i , the characteristic polynomial
has at least one real negative eigenvalue.
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Proof. By the Fundamental Theorem of Algebra, our non-zero single variable characteristic
polynomial of degree three will have exactly three roots. By Descartes’ Rule of Signs, there
are no positive solutions. Thus, the characteristic polynomial has either 3 negative real roots
or 1 negative real root and two complex conjugates.
Lemma 3.2. Let ρ∗ be the value of ρ in the region of existence of E+i such that for D2, the
second Hurwitz determinant, D2(ρ
∗) = 0. At ρ = ρ∗, η2(ρ
∗) and η3(ρ
∗) are purely imaginary
and conjugate eigenvalues of the Jacobian evaluated at E+i .
Proof. At ρ = ρ∗, D2(ρ
∗) = 0 ⇐⇒ d1d2 = d3(ρ∗). Thus, we can write the characteristic
equation of the Jacobian evaluated at E+i as
η3 + d1η
2 + d2η + d1d2 = 0
⇐⇒
η3 + (dI + dV + dTRo)η
2 + ((dI + dV )dTRo)η + (dI + dV + dTRo)((dI + dV )dTRo) = 0
which has solutions
η1 = −(dI + dV + dTRo)
η2 = −
√
−dTRo(dI + dV )
η3 =
√
−dTRo(dI + dV )
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(a) Real part of eigenvalues η2 and η3 (b) Imaginary part of eigenvalues η2 and η3
Figure 3.7 Real part and imaginary part of eigenvalues η2 and η3 as functions of the bifur-
cation parameter ρ. They cross the imaginary axis at ρ = ρ∗ ≈ 0.165 when using parameter
values from Table 3.1.
Theorem 3.3. In the E+i region of existence, there exists a Hopf bifurcation at the critical
value ρ = ρ∗.
Proof. Based on Hopf bifurcation theory, with the proof of Lemmas 3.1 and 3.2, we need
only show the transverality condition, dη2(ρ)
dρ
6= 0, holds at ρ = ρ∗ to prove the existence of a














3[η2(ρ)]2 + 2d1[η2(ρ)] + d2































6= 0 if and only if d′3(ρ∗) 6= 0
Given d3(ρ) = −dIdV2 A(ρ)B(ρ)
where A(ρ) = (−b(ρ) +
√


















and B′(ρ∗) = 4cT k(A(ρ
∗)+2cT k−2ρA′(ρ∗))
(A(ρ∗)+2cT k)3
Within the E+i region of existence d3(ρ) > 0 and b(ρ)
2−4ac > 0 holds true for all values of
ρ. When ρ = ρ∗ the parameter location in the (Rm, Ro)-plane is in the portion of the region
where b(ρ∗) < 0. Based on these assumptions both A(ρ∗) > 0 and A′(ρ∗) > 0. Moreover,
B(ρ∗) < 0 in order to maintain the proper sign of d3(ρ
∗). It is sufficient that the sign of
B′(ρ∗) =⇒ sign of A(ρ∗) + 2cTk − 2ρA′(ρ∗) < 0 in order to claim d3
′
(ρ∗) 6= 0. A graphical
justification can be found in Figure 3.8.
3.4.5 Numerical Results of the Hopf Bifurcation
Numerical results were computed using the parameters and initial values from Table 3.1
with the exception of fixing λ = 7 and varying ρ to obtain the following graphs. The
first results, found in Figure 3.9, demonstrate the stability of the infected steady state with
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Figure 3.8 The region in the (Rm, Ro)-plane where B
′(ρ) < 0 includes the locations where
ρ = ρ∗.
a location in the (Rm, Ro) parameter plane in the light red region in which only Ei
+ is
locally asymptotically stable. In this region, the complex eigenvalues of the Jacobian matrix
evaluated at Ei
+ have negative real parts. The stability of Ei
+ can be seen in Figure 3.9(a)
where, in R3, all three populations are spiraling inward toward the corresponding values
of the infected steady state. The bifurcation parameter ρ is adjusted so that ρ ≈ ρ∗ and
the location on the parameter plane is at the border of the light red region and the white
region seen in Figure 3.3. The associated complex eigenvalues now have real parts which
are extremely close to zero. Looking again at our populations of interest in R3, we see the
emergence of a hole in Figure 3.10(a). The healthy T cells, infected T cells and viral load
populations are still spiraling inward to the corresponding values of the infected equilibrium
as t → ∞, but the populations will not attain these values. Finally, we increase ρ so that
the parameter plane location is completely in the white region. The associated complex
eigenvalues now have positive real parts. The populations of interest, once again, spiral
inward in R3 not to a single value but instead an orbit of values, see Figure 3.11(a).
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(a) TVI - plane (b) Long term behavior of the uninfected T
cell population
(c) Long term behavior of the virus population (d) Long term behavior of the infected T cell
population
Figure 3.9 With ρ = 0.5, parameter location is in the light red region (see Figure 3.3). Hence
associated complex eigenvalues are of the form α± iβ where α < 0 yielding a stable steady
state.
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(a) TVI - plane (b) Long term behavior of the uninfected T
cell population
(c) Long term behavior of the virus population (d) Long term behavior of the infected T cell
population
Figure 3.10 With ρ = 0.123, parameter location is on the border of the light red and white
regions (see Figure 3.3). Hence associated complex eigenvalues are of the form ±iβ where
α ≈ 0 creating a hole, i.e. emergence of a stable orbit.
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(a) TVI - plane (b) Long term behavior of the uninfected T
cell population
(c) Long term behavior of the virus population (d) Long term behavior of the infected T cell
population
Figure 3.11 With ρ = 0.15, parameter location is in the white region (see Figure 3.3). Hence
associated complex eigenvalues are of the form α± iβ where α > 0 yielding a stable orbit.
62
3.5 Conclusion
In the standard dynamic model, results showed steady states to be globally asymptot-
ically stable and the stability of these equilibria had no dependence on initial viral load
nor the healthy T cell count at the time of infection. The current model shows a region
of bistability in which both the infection free and persistent infection steady states are lo-
cally asymptotically stable. Therefore, the initial conditions, along with parameter values,
determine long term behavior. The healthy T cell count at the time of infection or during
treatment has the strongest determination of the long term behavior as shown in Figure 3.6.
Hence, the model displays that a patient who under goes therapy early on or even prior
to infection has a possible chance of clearing infection or maintaining a higher T cell count
throughout infection. By contrast, a low T cell count can lead to a chance for clearance, as
shown by the long time asymptotics in Figure 3.6. With the emergence of a Hopf bifurcation,
we now have a region in the parameter plane which mimics the biological behavior known
as oscillatory blips. Oscillatory blips are spikes in the viral load size which occur during the




A STOCHASTIC EPIDEMIC MODEL FOR THE 2014 EBOLA OUTBREAK IN WEST
AFRICA; AN ANALYSIS OF GUINEA, LIBERIA AND SIERRA LEONE
Modified from a paper to be submitted to Statistics in Medicine.
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4.1 Abstract
During the 2014 Ebola outbreak in West Africa, extreme poverty, a dysfunctional health
care system, a distrust in government by citizens, a delayed response and local burial customs
all contributed to the epic proportions of individuals affected by the disease. With a high case
fatality rate and 57 - 59% of deaths from reported cases occurring in hospitals, it is imperative
that the medical community have a more informed understanding of the most influential
methods by which the disease spreads. We develop a mathematical model for this Ebola
outbreak to capture the dynamics within the avenues of transmission in the three countries
most affected: Guinea, Liberia and Sierra Leone. We fit the model to publicly available data
provided by the World Health Organization. We derive a novel stochastic branching SEIR
model to employ Approximate Bayesian Computation to estimate distributions of the forces
of infection and quantify the associated uncertainty of these values. Results indicate rates of
transmission from the infectious community and the hospitalized and infectious community
to be low within all three countries. The rate of transmission from the deceased and infectious
population is relatively high in Guinea. The frequency for which infectious individuals enter
the hospital is notably lower in Guinea and Sierra Leone. The large discrepancies between
these parameter values among the countries indicates a need for mitigation strategies to be
focused on earlier hospitalization and proper burial procedures which respect cultural beliefs.
5Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
6Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
7Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
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4.2 Introduction
Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, belongs to a
group of viral infections characterized by high fever, petechiae, internal bleeding, hypotension
and shock. Because the natural reservoir host of Ebola virus has not yet been identified, the
way in which the virus first appears in a human at the start of an outbreak is unknown [28].
It is believed that the virus is transmitted to humans by contact with an infected animal
either by touch or ingestion. According to the World Health Organization (WHO), Ebola is
spread from human to human through direct contact with blood or body fluids (including
but not limited to urine, saliva, sweat, feces, vomit, breast milk, and semen), and objects
(like needles, syringes, bedsheets, etc.) that have been contaminated with bodily fluids from
a person who is infected with Ebola or the body of a person who has died from Ebola. When
a person contracts the virus there is an incubation period prior to becoming infectious and
the time between exposure and the onset of symptoms ranges from 2 to 21 days [29].
The average EVD case fatality rate is around 50% and case fatality rates have varied
from 25% to 90% in past outbreaks [29]. Surprisingly, even postmortem a person remains
infectious for a period of time. Viable virus can persist for 7 days or more on surfaces
of bodies, confirming that transmission from deceased persons is possible for an extended
period after death [30]. This can be particularly devastating to the prevention of the disease’s
spread as cultural burial rites in areas of West Africa include washing, touching or kissing the
body of a deceased person. Since Ebola is easily contracted through touch of a contaminated
person or surface, the environment of a hospital can become a major factor in minimizing
the spread of the infection. The Ebola epidemic in Kikwit, Democratic Republic of the
Congo, was recognized because of a nosocomial outbreak in Kikwit General Hospital [31]. A
nosocomial or hospital-acquired infection is one whose development is favored by the hospital
environment because it is easily spread from patient to patient or among hospital staff.
In this chapter, we study the largest Ebola outbreak in history which occurred in West
Africa beginning in 2013. The first case was reported in Guinea in December 2013. By
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March of the following year, Guinea had a total of 103 reported cases with 8 cases reported
in neighboring Liberia and 6 cases in Sierra Leone. On August 8, 2014 the World Health
Organization (WHO) declared the Ebola epidemic in West Africa a Public Health Emergency
of International Concern (PHEIC). Recorded Ebola patients develop antibodies that last for
at least 10 years [32]. This motivates the need to retroactively study the West African Ebola
outbreak in preparation to combat a future outbreak. It is our aim to use a model which
incorporates the three main avenues of transmission of Ebola during this outbreak; namely
contact with infectious, hospitalized, and traditionally buried individuals. We will use the
data as reported by WHO from Guinea, Liberia, and Sierra Leone to inform our estimation
of the transmission rates of these three populations within each country as well as the average
number of days before infectious individuals entered the hospital. We hold parameters of the
characteristics of the disease such as incubation time or recovery time constant to examine
the existence of heterogeneity in the transmission rates among our countries of interest. The
authors in [33] look at the spatial structure of Ebola outbreaks but simplify the disease
process. By maintaining a standard SEIR model with a spatial component, [33] is not able
to incorporate a more complex branching structure in the model.
A branching SEIR model is introduced in [8] using a system of ordinary differential
equations incorporating the effects of transmission by means of three populations among
the communities where Ebola outbreaks are ongoing, but the authors choose to exclude
stochastic effects from their study. The authors in [34] introduce a similar branching SEIR
model for capturing Ebola dynamics with the exception that all individuals are traditionally
buried regardless of hospitalization. The authors in [34] develop a stochastic model based
on the ODE branching SEIR at the individual level assuming a binomial distribution for
compartment transfer to calculate estimation of the force of infection from the same three
groups of interest as described in [8] by means of a Maximum Likelihood Estimation (MLE).
However, MLE has the potential to find only local maxima and we will demonstrate that
the likelihood function of such models is multimodal. Hence, we derive a stochastic model
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to perform Bayesian inference at the population level based on the ODE system presented
in [8]. Using data from the 2015 West Africa outbreak to inform the estimation of our
parameters of interest (e.g., the forces of infection from infectious, hospitalized and tra-
ditionally buried individuals) we incorporate uncertainty about unobserved variables and
error in the reporting process. Similar to [35], we incorporate a method of obtaining ap-
propriate conditional binomial distributions for transitions between compartments by way
of embedding the deterministic system into a stochastic process as described in [36]. The
method of incorporating a Poisson contact distribution among the susceptible and infectious
individuals to derive the probability of infection of a susceptible individual after exposure
to one of the three types of infectious individuals is the same as found in [35] and [37].
However, because the model has a branching SEIR structure, we deviate from [35] to derive
two conditional multinomial distributions for the infectious and hospitalized populations.
In this way, simulations can be computed at the population level, increasing computational
efficiency. Approximate Bayesian Computation (ABC) is used to estimate the posterior dis-
tributions of the parameters of interest constructing the entire posterior to assess all of the
local maxima, and therefore obtain the global maximum.
In the following section, we explain the branching SEIR ODE model posed in [8] followed
by the derivation of the method by which this deterministic system is embedded into a
stochastic process. A description of the ABC algorithm used to obtain posterior distributions
completes Section 4.3. In Section 4.4, we describe the method by which the 2014 Ebola
data, as reported by the Center for Disease Control [38], was cleaned along with the results
of the approximate posterior distributions. The last section is reserved for discussion and
conclusions.
4.3 Methods
The dynamics of the spread of Ebola is first introduced by way of a deterministic model in
Section 4.3.1. Our approach of embedding this deterministic system into a stochastic process
is explained in detail in Section 4.3.2. The final subsection within Section 4.3 provides the
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algorithm for which computations are performed on the stochastic model.
4.3.1 The Deterministic Model
The spread of Ebola requires direct contact with blood or bodily fluids of a person who
is sick with or has died from Ebola, objects that have been contaminated by these bodily
fluids, infected fruit bats or primates and possibly from contact with semen from a man who
has recovered from Ebola [39].
Figure 4.1 A schematic representation of (4.1), modeling the progression of Ebola in a
fully susceptible population. The susceptible population, S, transfers to E, the exposed
population, via one of three methods (indicated by orange arrows); 1.) contact with a
deceased but infectious person, D 2.) contact with an infectious person, I, 3.) contact with
an infectious hospitalized person, H. The exposed individual will experience a latent period
prior to becoming infectious and transitioning to I. The infectious population can then
transfer to one of three compartments, D - deceased and infectious, R - recovered, or H -
hospitalized and infectious, with varying rates of transfer. Those individuals in D will, after
some time, no longer be infectious and transfer to B, properly buried and non-infectious.
Those individuals in H will transfer to one of two end states, B or R.
In Figure 5.1, the susceptible population, S, can contract Ebola through contact, as
previously described, with an individual from one of three compartments, I - infectious
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population, H - hospitalized and infectious population, or D deceased and infectious popu-
lation at rates β1, β2, and β3 respectively. Once transmission occurs the formerly susceptible
individual transfers to the exposed compartment E, and is labeled infected but not yet
infectious. An exposed individual, waiting a latent period of 1/δ, will not be considered
infectious until symptoms are present at which time the exposed individual will transition to
the infectious population, I. Those in the infectious population may seek medical attention
and be hospitalized. The proportion of the infected population that becomes hospitalized,
H, is denoted by ψ. The hospitalized population will then either recover at a rate, γ2 and a
proportion 1 − ρ2 will transfer to R or die at a rate γ2 and be buried by sanitary methods
so that they are no longer infectious, and a proportion ρ2 will transfer to B. The remaining
infectious population at a rate γ1 will either die and remain infectious, transitioning to D or
recover, transitioning to R. The proportions of these transferring infectious population are
indicated by ρ1 and 1 − ρ1, respectively. Deceased individuals in D will remain infectious
for a period of time at which point they will no longer be infectious and therefore transfer
to B, the deceased and non-infectious population. The system is described by the following
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= ρ1γ1I − ωD
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= ωD + ρ2γ2H
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The population state variables are described within Table 5.1 and the parameters are
presented in Table 5.2. The total population, N , remains constant in the system, i.e. S +
E + I +H +D +B +R = N for the duration of the epidemic.
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Table 4.1 Description of populations state variables
S Number of susceptible individuals
E Number of infected individuals who are not yet infectious
I Number of infectious individuals
H Number of hospitalized infectious individuals
D Number of deceased infectious individuals
B Number of deceased non-infectious individuals
R Number of recovered individuals
Table 4.2 Description of parameters within the Ebola model. Dimensions are provided in
parentheses.
β1 Rate of transmission of the disease from the infectious population, I.
(Dimensionless)
β2 Rate of transmission of the disease from the deceased and infectious population, D.
(Dimensionless)
β3 Rate of transmission of the disease from the hospitalized and infectious population, H.
(Dimensionless)
δ Per capita rate of progression of individuals from the exposed state to
the infectious state. (Time−1)
The average duration of the latent period is 1/δ.
γ1 Per capita recovery rate for individuals who are not hospitalized. (Time
−1)
The average duration of the infectious period for individuals not in the
hospital is 1/γ1.
ψ Per capita rate for individuals to enter the hospital. (Time−1)
The average wait time for an infectious individual to enter the hospital is 1/ψ
γ2 Per capita recovery rate for individuals who are hospitalized. (Time
−1)
The average duration of the infectious period for individuals in the hospital is 1/γ2.
ρ1 The proportion of the infectious population who die of the disease but are
never hospitalized.
(Dimensionless)
ω Per capita rate for deceased and infectious individuals to be properly buried
and no longer be infectious. (Time−1)
The average time until a deceased and infectious individuals is no longer
infectious is 1/ω.
ρ2 The proportion of the hospitalized and infectious population who die of the disease
and are properly buried. (Dimensionless)
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4.3.2 An Embedded Stochastic Model
The method by which we embed Model (4.1) into a stochastic process [36] is summarized
in the following paragraphs. We first introduce the means by which the continuous process
of the spread of the disease is discretized. We have carried over from Model (4.1) the
assumption that the people are homogeneous in the population. Exploiting the assumptions
of exponentially distributed wait times and Poisson contact distributions, we derive the
binomial and multinomial distributions for the stochastic components of Model (4.2, 4.3) in
subsequent sections.
We know specific rates for the transfer of individuals from one compartment to another.
We assume the system to be conservative, i.e. S(t)+E(t)+I(t)+H(t)+D(t)+B(t)+R(t) = N
for all t where N is the total population. This assumption is appropriate as the population
size is considered large and our domain of time in the model is short. By discretizing the
continuous process into a discrete number of time steps over which the data are collected,
we can approximate the rates of change for the populations by differences between time
steps. We denote Tk as the number of discrete time steps, not necessarily of equal duration,




hj + 1 = T , and T indicates the total number of days for which data was collected.
Given the state of the process at time t, we account for all the events that may occur during
the time interval (t, t+ hj]. Our model now takes the following form
St+hj = St − E∗t+hj


























































The compartments are labeled as follows; S - susceptible individuals, E - exposed but not
infectious individuals, I - infectious humans, H - hospitalized and infectious individuals,
D - deceased and infectious individuals, B - deceased and non-infectious individuals, R
- recovered individuals. All quantities are counts and quantities denoted by an asterisk
represent a transition count. When individuals in a compartment may transition to two or
more compartments such as IR∗t+hj and ID
∗
t+hj
, two letters are used to denote the transition.
In these cases, the first letter denotes from which compartment the individual transitions
and the second denotes the compartment to which the individual transitions. The transition
compartments are the stochastic elements of the model. For individuals waiting to transition
from one compartment to another (e.g., exposed to infectious), we assume an exponential
distribution for all wait times [36].
4.3.2.1 Exponential Distributions for Wait Times
We derive the wait time of an exposed individual to transition through the latent pe-
riod to the infectious population as explained in [36]. We consider the −δE term from our
deterministic model and note that for dE
dt
= −δE the solution is the exponential function
E(t) = e−δt. Under the assumption of a homogeneous population, we let W be the random
variable for the duration of the latent time for an individual to transition from the exposed
compartment, E to the infectious compartment, I. Thus, W ∼ Exp(δ) with a cumulative
distribution function F (x) = 1−e−δx and an expected value, E(W ) = 1/δ. Given an exposed
individual, E[i], at time t, the conditional probability of remaining exposed at time t + hj,
denoted qE, is derived in the following way,
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qE = P [W > t+ hj|W > t]
=
P [W > t+ hj ∩ W > t]
P [W > t]
=
P [W > t+ hj]
P [W > t]
=
1− P [W ≤ t+ hj]
1− P [W ≤ t]
=
1− (1− e−δ(t+hj))




Note that the probability no longer depends upon time. This may be counterintuitive
as it seems that an individual who has remained in the Exposed compartment for a longer
period of time should have a higher probability of transition to the Infectious compartment
than an individual who has spent less time in the Exposed compartment. However, the
assumption of exponential distributions for wait times, while questionable, maintains the
exponential assumptions implied in the ODE system. Moreover, the assumption has little
effect on model fit as the calculations are summations of random variables which become
large enough for the Central Limit Theorem to apply. Thus, the exponential assumption is
unlikely to have much of an effect on model fit. To count the number of exposed individuals
who become infectious during [t, t+hj) for t ≥ 1, we use ξit to denote i.i.d Bernoulli random
variables indicating that individual [i] transfers from E to I at time t namely,
ξit =
{
1 if ith person becomes infectious,
0 if ith person does not become infectious.





ξit . The distribution of the transition compartment, I
∗, is a summation of i.i.d
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Bernoulli random variable and thus a Binomial distribution,
I∗t+hj ∼ Bin(Et, 1− e
−δhj)
with the number of trials corresponding to the population size, Et, and a probability of
success of pE = 1− qE = 1− e−δhj .
4.3.2.2 Poisson Probability of Contact
To obtain the total of newly exposed individuals at each time step, we assume that the
number of contacts between a susceptible person and an infectious person from one of the
three infectious populations, I, D, or H follows a Poisson distribution. This derivation
follows the work of [33, 37] closely but employs a compartmental version instead of spatial.













For a single person from the susceptible population, S[i] say, there are three channels of
becoming infectious: 1. contact with an infectious person, I[i], 2. contact with a deceased
individual that is still infectious, D[i], and 3. contact with an infectious person who is
hospitalized, H[i]. Let pI , pD, pH ∈ (0, 1) be the associated conditional probability that
S[i] becomes latently infected by contact with an individual from the respective group, all






are the proportions of infectious people available
to make contact with S[i] from each group during a particular time interval, (t, t + hj].
Assuming random mixing, we obtain the probability per contact with an infected individual















respectively. Thus, the probability per contact with an infected individual from a particular
compartment, I, D, or H, for which S[i] does not become latently infected during (t, t+ hj]
is
qI(t) = 1− pI(t)
qD(t) = 1− pD(t)
qH(t) = 1− pH(t).
We assume a Poisson distribution for the random variables, CI,i(t), CD,i(t), and CH,i(t),
representing the number of contacts S[i] has with individuals from I, D, or H during (t, t+hj].
Since we require a non-negative support, a Poisson distribution is seen as a good assumption
for communicable disease which spreads through non-intimate contact [35]. With CI,i(t) ∼
Pois(λIhj), CD,i(t) ∼ Pois(λDhj),and CH,i(t) ∼ Pois(λHhj) where λI , λD, and λH are the
unknown average number of contacts per corresponding compartment per time interval, we















cH,i = 0, 1, 2...
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We assume Ci and Ci′ are independent for i 6= i′ for all compartments. Let Q(It) be
the probability that a susceptible person does not become infected via an individual from
compartment I. Let Q(Dt) be the probability that a susceptible person becomes does not
become infected via an individual from compartment D. Let Q(Ht) be the probability that
a susceptible person does not becomes infected via an individual from compartment H.
Moreover, the probability of an individual S[i] not becoming infected by any one of these
three methods is given by
Q(t) = Q(It)Q(Dt)Q(Ht)
due to the fact that the occurrence of one event yields no information about the occurrence
of another event. Thus, the probability a susceptible individual becomes infected by one of
these three ways is calculated as follows:























































































































The parameters, λI , λD, λH , pI , pD, pH , are non-indentifiable as individual parameters.
However, their products, (contact rate) × (probability of infection) = (transmission rate),
is identifiable. Thus, we can replace λIpI , λDpD, λHpH with βI , βD, βH , the corresponding
transmission rates from the deterministic model. To count the number of susceptible indi-
viduals who become infected during (t, t + hj] for t ≥ 1, we use ξit to denote a Bernoulli
random variable indicating individual [i] transfers from S to E at time t via transmission
from an individual in compartment I, compartment D, or compartment H, so that
ξit =
{
1 if ith person is infected,
0 if ith person is not infected.
Note that ξit is a collection of conditionally independent, identically distributed Bernoulli
random variables with probability P (t) as described above. Therefore, the newly exposed

















There are two populations in the model, I and H, for which individuals transitioning to
one of two or more compartments is possible. Therefore, we provide a novel derivation to
obtain the probabilities associated with the possible paths of transition for these individuals.
Infectious individuals, I, can either die and be improperly buried, enter the hospital, or re-
cover implying transfer to compartments H, D, or R, respectively. Hospitalized individuals,
H, will either die and be properly buried or recover while in the hospital implying transfer
to compartments B or R, respectively. Without loss of generality, we will derive only one of
the probabilities in the first scenario where an infected individual can transfer to either H,
D, or R. Individuals who enter these compartments on day t + hj make up the size of the
H∗, IR∗, and ID∗ compartments, respectively.
Let W1 ∼ Exp(ψ),W2 ∼ Exp(γID),W3 ∼ Exp(γIR) be the random variables for the du-
ration of the wait for an individual to enter one of the three compartments, H, D, or R.
The derivation of the wait time is similar to the derivation of the latent transition time [36].
Without loss of generality, we will examine the probability of an infected individual [i] on
day t becoming hospitalized on day t+ hj. On day t, we define the following
C1 = {W1 > t : “not going into the hospital”}
C2 = {W2 > t : “not dying and remaining infectious”}
C3 = {W3 > t : “not recovering”}
where, C = {C1 ∪C2 ∪C3} : disease process at time τ ∈ [t, t+ hj). On day t+ hj, we define
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A1 = {W1 ≤ t+ hj|C : “going into the hospital”}
A2 = {W2 ≤ t+ hj|C : “dying and remaining infectious”}
A3 = {W3 ≤ t+ hj|C : “recovering”}
Hence, the domain of disease process during [t, t + hj) is given as C. We produce the
following Venn diagram to denote the occurrence of an individual [i] transitioning to one of





Figure 4.2 C is the state space of the disease process at time τ ∈ [t, t+ hj)
Because of the constraints of our model, in that no infected individual can move to more
than one compartment on any given day, we must exclude these impossible events from the
sample space. We denote the set of individuals who transition to more than on compartment
in Figure 4.3 where B1 = A1 ∩ A2 ∩ A3c, B2 = A1 ∩ A2c ∩ A3, B3 = A1c ∩ A2 ∩ A3, and
B4 = A1 ∩ A2 ∩ A3.
Dependence is introduced through truncation because when one event occurs, i.e. W1 ≤
t + hj|C, all other events become probability zero events. Thus we have a conditional
probability for the probability of an infected person going to the hospital on day t + hj is
denoted
p1 = P (A|C ∩ Bc) =
P (A ∩ (C ∩ Bc))
P (C ∩Bc) =
P (A ∩ C) ∩ (A ∩ Bc)









Figure 4.3 The set B = {B1 ∪B2 ∪B3 ∪B4} indicates the set for which an individual would
transition to more than one compartment during time τ of the disease process.
Note that A ∩ C = A and C ∩ Bc = Bc since C represents the entire space. Similarly,
A ∩Bc = A. Hence, the probability an infected individual enters the hospital on day t+ hj
simplifies to:
p1 = P (A|C ∩ Bc)
where A = A1 ∩ A2c ∩ A3c and Bc = B1c ∩ B2c ∩ B3c ∩ B4c. The Venn diagram of the




Figure 4.4 We have conditioned on not going to two or more compartments so that our new
state space for the disease process at time τ is indicated by Bc (orange).
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We then derive the probability of an individual in the infectious compartment I on day
t transitioning to the hospitalized compartment H on day t+ hj in the following way,
p1 = (A|C ∩Bc)
=
P (A ∩ (C ∩ Bc))
P (C ∩Bc)
=
P (A ∩ C) ∩ (A ∩ Bc)





P (A1 ∩ A2c ∩ A3c)
P (B1
























where α = 1−[{1−exp(−ψhi)}{1−exp(−γIRhi)}{1−exp(−γIDhi)}+{1−exp(−ψhi)}{1−exp(−γIRhi)} exp(−γIDhi)+
{1− exp(−ψhi)} exp(−γIRhi){1− exp(−γIDhi)}+ exp(−ψhi){1− exp(−γIRhi)}{1− exp(−γIDhi)}].
With similar calculations we would derive the conditional transfer probabilities p2 and p3
for compartments IR∗ and ID∗, respectively. Hence we let Ψ[j] denote the random variable
for the transition of an infected individual by
Ψ[j] ∼ Mult(1, (p1, p2, p3, 1− p1 − p2 − p3)′)
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where p1 is the probability of transitioning to the hospital, p2 is the probability of dying and
remaining infectious, p3 is the probability of recovering and 1−p1−p2−p3 is the probability
of remaining infectious without transitioning to a new compartment. We assume the random
variables Ψ[j] are independent and identically distributed for all j and thus by means of the
summation of Ψ[j] for all j at time t we can construct the random variable for the counts of




, ID∗t+hj , I
s
t+hj
)′ ∼ Mult[It, (1− exp(−ψhj)) exp(−γIRhj) exp(−γIDhj)/α,
(1− exp(−γIRhj)) exp(−ψhj) exp(−γIDhj)/α,
(1− exp(−γIDhj)) exp(−ψhj) exp(−γIRhj)/α,
exp(−ψhj) exp(−γIRhj) exp(−γIDhj)/α].
Similarly, the multinomial distribution for the transition of individuals in the hospitalized
compartment, H, at time t to either deceased and buried, HB∗, recovered, HR∗ or remaining
in hospital, Hs at time t+ hj is derived in the same way once again introducing dependence
through truncation so that when one event occurs all other events become probability zero





′ ∼ Mult[Hi, (1− exp(−γHBhi)) exp(−γHRhi)/ζ,
(1− exp(−γHRhi)) exp(−γHBhi)/ζ,
exp(−γHRhi) exp(−γHBhi))/ζ]
where ζ = 1− [{1− exp(−γHRhi)}{1− exp(−γHBhi)}].
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The stochastic components of the model are as follows:














, ID∗t+hj , I
s
t+hj
)′ ∼ Mult[It, (1− exp(−ψhj)) exp(−γIRhj) exp(−γIDhj)/α,
(1− exp(−γIRhj)) exp(−ψhj) exp(−γIDhj)/α,
(1− exp(−γIDhj)) exp(−ψhj) exp(−γIRhj)/α,
exp(−ψhj) exp(−γIRhj) exp(−γIDhj)/α]



















































where α = 1− [{1−exp(−ψhj)}{1−exp(−γIRhj)}{1−exp(−γIDhj)}+{1−exp(−ψhj)}{1−
exp(−γIRhj)} exp(−γIDhj)+{1−exp(−ψhj)} exp(−γIRhj){1−exp(−γIDhj)}+exp(−ψhj){1−
exp(−γIRhj)}{1− exp(−γIDhj)}],
ζ = 1− [{1− exp(−γHRhj)}{1− exp(−γHBhj)}].
Note α and ζ are chosen such that the probabilities in the multinomial distributions sum
to one. Ist+hj represents the count of individuals who are infectious at time i and remain
infectious at time t + hj. H
s
t+hj
represents the count of individuals who are hospitalized at
time t and remain hospitalized at time t+ hj.
4.3.3 ABC Algorithm and Computation
The conversion of Model (4.1) to Model (4.2, 4.3) will incorporate uncertainty into the
disease process and quantify the uncertainty of our parameters of interest, Θ = [β1, β2, β3, ψ].
Note that we have held constant and known the parameters listed in Table 4.3. These values
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Table 4.3 Fixed and Known Parameter Values
Parameter Fixed Value (days) Reference







Note: Parameters from the deterministic model have been renamed:
ρ1γ1 = γID, (1− ρ1)γ1 = γIR, ρ2γ2 = γHB, and (1− ρ2)γ2 = γHR.
relate to the medical characteristics observed during the outbreak which occurred in West
Africa in 2014. We use the values as calculated from Sierra Leone as this data is the most
neutral. Holding these parameters constant for all three countries will allow the data to
inform the model as to whether heterogeneity among the avenues of transmission exists
between the countries of interest. Model (4.2, 4.3) also allows for Bayesian inference on
parameter posteriors which have the form:
f(Θ|Y ) ∝ f(Y |Θ)π(Θ).
where f(Y |Θ) is the stochastic data model, which for fixed values of Θ can be used to
generate the random epidemic process, and π(Θ) is the prior distribution of the parameters.
Thus, given both the data model and the prior distribution, we are able to calculate the
posterior distribution f(Θ|Y ) up to a proportionality constant. This serves to update the
distribution of the biologically accepted parameter ranges by the actual epidemic data which
we denote as Y .
With a data model constructed as a product of binomials and multinomials with different
sample sizes and probabilities across every time point, finding the MLE to provide a point
estimate and standard deviation for parameter estimates may provide estimates outside of
84
the valid biological ranges and may suffer from issues stemming from multimodality. In SEIR
models, Markov Chain Monte Carlo (MCMC) methods produce parameter autocorrelation
in chains which becomes problematic for tuning and are also subject to difficulties stemming
from multimodality. We can avoid these obstacles via Approximate Bayesian Computation
(ABC). This method was introduced [41] to obtain an approximation of the true posterior
distribution, f(Θ|Y ). ABC will sample from the posterior by randomly choosing samples
from the prior that fit the data. Random draws, Θ∗, from the prior distribution will produce
generated data sets, X, which will be compared to our actual epidemic data set, Y by means
of a chosen distance metric. Those values of Θ∗ which generate data sets which fit the data
will be accepted as valid draws from the posterior distribution. This implicitly conditions
the posterior on Y . The algorithm of the computation is as follows where N is the total
number of accepted generated data sets X.
For j ≤ N
1. Draw Θ∗ ∼ Unif(ak, bk), where (ak, bk) is the corresponding range found in Table 4.4.
2. Generate X, time series data of the number of reported infectives, from Model (4.2,
4.3)
3. Calculate fitness of data using ρ(X, Y )
4. Set Θ[j] ← Θ∗ if ρ(X, Y ) ≤ ǫ and set j ← j + 1 else return to Step 1.
If the metric ρ(X, Y ), considered a distance between X and Y , is small enough, i.e.,
ρ(X, Y ) ≤ ǫ for some fixed small value, then π(Θ|ρ(X, Y ) ≤ ǫ) ≈ π(Θ|Y ). One often
uses sufficient statistics in defining ρ; these are statistics for which the data distribution
conditioned on the sufficient statistic is free of Θ (e.g. the sufficient statistic contains all
information about Θ that the full data set contains). By definition, the full data set is a
sufficient statistic for Θ. Since a sufficient statistic of lower dimension than the full data
85
Table 4.4 Ranges for Uniform Distributions
Parameter Range





set cannot be readily computed for our model, we consider a point-wise envelope metric
comparing point by point the L1-norm at every time step. Heuristically, if every data point
of X and Y is close, then we must have that any statistics computed from X and Y ,
including sufficient statistics, will also be close. For the ABC method, the exact posterior
distribution of Θ can be found by accepting the simulated data set in which X = Y . This
is computationally infeasible, so we consider X, such that Xt
Yt
∈ (ǫ1, ǫ2) for all time steps t
with corresponding peak week and epidemic duration to Y , as an acceptable epidemic. We
call (ǫ1, ǫ2) the envelope of tolerance around the observed data set, Y , which is a common
method for assessing stochastic SEIR model fit [35, 37, 42].
4.4 Data Analysis
The next two sections explain various aspects of the data analysis performed on Model
(4.2, 4.3). We first describe the method of data cleaning applied to the data. In Section
4.4.2, we provide the results as compiled from the data.
4.4.1 Data Cleaning
The data used in this study was obtain from the Center for Disease Control [38]. The
cumulative number of reported cases is recorded during each Epidemiological Week (EW).
Note that within all three countries the cumulative number of cases reported, at varying
points in time during the outbreak, are reported as decreased in value. Since we maintain
the populations within the countries as constant, we clean the data by carrying forward the
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total number of Ebola cases until the reported number is larger. For each country we assume
that all individuals of that country are part of the initial susceptible population. The total
populations were recorded in 2014 as Guinea: 12,112,127 Liberia: 4,345,123 and Sierra Leone:
6,247,243 [43]. With the cleaned data and total country populations we can then calculate
the initial sizes of our populations of interest: susceptible, exposed, infectious, deceased and
infectious, hospitalized and infectious, buried and non-infectious, and recovered. We choose
start days of the epidemic for each country after the cumulative case count starts to display
a generally increasing trend, which we take to indicate the data were sufficiently accurate
to begin analysis. The start date of the epidemic varies by country, see Table 4.5. With
the initial date determined, we can then calculate the initial conditions based on the data.
To find the initial number of exposed individuals, E0, we take the current total number of
cases reported and look at the total number of cases nine days later as this corresponds
to the length of the latent incubation period. To calculate the initial number of infectious
individuals, I0, we find the total number of cases nine days prior to the start of the epidemic
to determine the number of exposed who would now currently be infectious. The initial
value of the dead and non-infectious population, B0, is the total number of cases reported
on the start date of the epidemic minus I0. We assume all other initial population sizes are
zero. The calculated values are summarized in Table 4.5.
Table 4.5 Initial Conditions on Day 1 of Ebola Epidemic per Country
Guinea Liberia Sierra Leone
Dependent variables / Populations
Day 1 5.23.14 6.24.14 5.28.14
Susceptible 12, 111, 912 4, 345, 016 6, 247, 162
Exposed 33 56 65
Infectious 25 17 10
Hospitalized 0 0 0




Recovered 0 0 0
Total Population 12, 112, 127 4, 345, 123 6, 247, 243
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4.4.2 Results
In the following section, we display the approximate posterior distributions obtained from
10,000 acceptances of the ABC algorithm (Section 4.3.3) for our parameters of transmission
rates via infectious, hospitalized, and traditionally buried individuals as well as the per capita
rate individuals to enter the hospital, Θ = [β1, β2, β3, ψ]





















(a) Guinea - β1


















(b) Guinea - β2




















(c) Guinea - β3






















(d) Guinea - ψ
Figure 4.5 Kernel density plots of the parameters of interest.
With parameters displaying multimodal posterior distributions, simply finding the mean
or mode of the marginal distributions would not accurately represent the joint distribution
of Θ = (β1, β2, β3, ψ). Hence, we calculate the joint mode estimate or the combination
of parameter values which is accepted most often by the ABC algorithm. We provide the
standard deviation of the marginal distributions as there is no corresponding joint standard
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(a) Liberia - β1















(b) Liberia - β2





















(c) Liberia - β3






















(d) Liberia - ψ
Figure 4.6 Kernel density plots of the parameters of interest.
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(a) Sierra Leone - β1
















(b) Sierra Leone - β2



















(c) Sierra Leone - β3



















(d) Sierra Leone - ψ
Figure 4.7 Kernel density plots of the parameters of interest.
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deviation. See Table 4.6 for the joint mode estimates and standard deviations for each
country.
Table 4.6 Joint Mode Estimates with Marginal Standard Deviation per Country
Guinea Liberia Sierra Leone
Dependent variables / Populations
β1 ; s.d. 0.0050 ; 0.0003 0.0311 ; 0.0003 0.0050 ; 0.0004
β2 ; s.d. 0.3958 ; 0.0194 0.1092 ; 0.0217 0.0311 ; 0.0037
β3 ; s.d. 0.0558 ; 0.0104 0.0177 ; 0.0026 0.0431 ; 0.0181
ψ ; s.d. 0.0769 ; 0.1146 0.7436 ; 0.0676 0.0513 ; 0.0010
4.5 Conclusion
We presented in this chapter a branching SEIR stochastic model to quantify the forces
of infection which compelled the 2014 Ebola outbreak in West Africa to be categorized
as the largest Ebola outbreak in history. Maintaining the value of the parameters related
to the biological progression of the disease as fixed and known enabled an examination of
heterogeneity among the methods of spread between Guinea, Liberia and Sierra Leone. We
generated the stochastic Model (4.2, 4.3) by embedding the deterministic Model (4.1) into a
stochastic process. The ABC method was then implemented to obtain approximate posterior
distributions and the inherent uncertainty in the values of the forces of infection, as well as
the per capita rate of hospitalization of infected individuals. We find that the forces of
infection from the infectious and the hospitalized and infectious populations have distinctly
peaked posteriors. In all three countries, the rates of transmission from these two groups are
less than or equal to 0.056. There was a large discrepancy among the frequency by which
infectious individuals went to the hospital. Both Guinea and Sierra Leone had significantly
lower rates of individuals entering the hospital than Liberia. The global maxima for ψ
varies between these countries with a global maxima of 0.077 in Guinea, 0.0513 in Sierra
Leone, and 0.74 in Liberia. Results indicate that while transmission of Ebola does occur
from hospitalized individuals and was the highest rate of transmission in Sierra Leone at
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0.043, the most significant rate of transmission was due to traditional burials in Guinea
and Liberia. In Guinea, the rate of transmission from traditional burial practices is 0.40.
Transmission from traditional burial practices is also the most frequent avenue of spread in
Liberia with a rate of 0.11. It is interesting to note that with a higher frequency of infectious
individuals entering the hospital, Liberia had a lower rate of transmission from traditional
burials than Guinea. There is no evidence of a causal relationship but this does indicate
that mitigation strategies might be most effective by focusing on earlier hospitalizations of
infectious individuals. Similarly, with high rates of transmission due to traditional burial
practices, further investigation of sanitary burial procedures which respect cultural beliefs
may significantly lower the spread of future Ebola outbreaks.
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CHAPTER 5
ESTIMATING THE REPRODUCTIVE NUMBER, TOTAL OUTBREAK SIZE, AND
REPORTING RATES FOR ZIKA EPIDEMICS IN SOUTH AND CENTRAL AMERICA
Modified from a paper submitted to Epidemics.
Deborah P. Shutt8, Carrie A Manore9, Stephen Pankavich10, Aaron T. Porter11 and Sara
Y. Del Valle12
5.1 Abstract
As South and Central American countries prepare for increased birth defects from Zika
virus outbreaks and plan for mitigation strategies to minimize ongoing and future outbreaks,
understanding important characteristics of Zika outbreaks and how they vary across regions
is a challenging and important problem. We develop a mathematical model for the 2015
Zika virus outbreak dynamics in Colombia, El Salvador, and Suriname. We fit the model to
publicly available data provided by the Pan American Health Organization, using Approx-
imate Bayesian Computation to estimate parameter distributions and provide uncertainty
quantification. An important model input is the at-risk susceptible population, which can
vary with a number of factors including climate, elevation, population density, and socio-
economic status. We informed this initial condition using the highest historically reported
dengue incidence modified by the probable dengue reporting rates in the chosen countries.
The model indicated that a country-level analysis was not appropriate for Colombia. We
then estimated the basic reproduction number, or the expected number of new human infec-
tions arising from a single infected human, for El Salvador and Suriname with a median of
8Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
9Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87544, The New
Mexico Consortium, Los Alamos, NM 87544
10Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
11Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO 80401
12Information Systems and Modeling, Los Alamos National Laboratory, Los Alamos, NM 87544
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4.3 and 5.3, respectively. We estimated the reporting rate to be around 16% in El Salvador
and 18% in Suriname with estimated total outbreak sizes of 73,395 and 21,647 people, re-
spectively. The uncertainty in parameter estimates highlights a need for research and data
collection that will better constrain parameter ranges.
5.2 Introduction
Mosquito-borne diseases contribute significantly to the overall morbidity and mortality
caused by infectious diseases in Central and South America. Newly emergent pathogens,
such as Zika virus in 2015, highlight the need for data and models to understand the public
health impact of associated diseases and develop mitigation strategies to combat their spread.
In particular, since Zika virus is a newly emergent pathogen in the Americas, its impact on
the näıve population is relatively unknown.
The disease was first discovered in isolation from a rhesus macaque in the Zika forest of
Uganda in 1974 [44]. While infrequent human cases were confirmed in later years in both
Africa and Southeast Asia, it was not until April 2007 that an outbreak outside of these
traditional areas occurred on Yap Island in the North Pacific [45], and this was followed by
another outbreak occurring in French Polynesia beginning October of 2013 [46]. However,
the most significant Zika outbreak began within Central and South America in 2015 [47] and
is currently ongoing. Thus far it has resulted in an estimated 714,636 infections, which in-
cludes both suspected and confirmed cases within Latin American and Non-Latin Caribbean
countries (accessed Jan 10, 2017) [48]. This study focuses on the behavior of the current
burgeoning epidemic in Colombia, El Salvador, and Suriname.
Zika is transmitted to humans primarily through bites from infected Aedes aegypti and
Aedes albopictusmosquitoes. The transmission is in both directions, that is, infected mosquitoes
infect humans and infected humans infect mosquitoes. Upon transmission of the virus from
mosquito to human, an individual will become infectious within 3 to 12 days. Symptoms of
infection include fever, rash, joint pain, conjunctivitis, muscle pain and headache. Recovery
from Zika virus disease may require anywhere from 3 to 14 days after becoming infectious, but
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once contracted humans are immune from the virus for life. Many people infected with Zika
may be asymptomatic or will only display mild symptoms that do not require medical atten-
tion. An estimated 80% of persons infected with Zika virus are asymptomatic [45, 49, 50].
Thus, there is a high occurrence of under-reporting for confirmed or suspected Zika cases.
In fact, the number of infected individuals who report their symptoms is estimated to be
between 7% and 17% [46] of the total number infected by the virus.
Zika can also be transmitted vertically, as a mother can pass the virus to her child
during pregnancy, and this can lead to a variety of developmental issues. Most notably, Zika
is a cause of microcephaly and other severe fetal brain defects [5]. Recent evidence further
suggests an association between the virus and a higher incidence of Guillain-Barré syndrome,
a disease in which the immune system damages nerve cells causing muscle weakness and
sometimes paralysis [51]. The potential for sexual transmission of Zika virus has also been
confirmed [52]. For instance, the Center for Disease Control (CDC) has determined that
Zika can remain in semen longer than in other body fluids, including vaginal fluids, urine,
and blood. It should be noted, however, that while these latter means of transmission exist,
the number of new human infections produced in this way is relatively low compared to
mosquito-borne infections [53, 54], and therefore, in the interest of simplicity and reducing
the number of parameters to fit, we will neglect them in formulating a model.
In general, mathematical modeling has been extensively used to understand disease dy-
namics and the impact of mitigation strategies [55]. A few recent papers have developed
models that focus on the behavior of the Zika epidemic. For example, Gao et al. [56], pro-
posed an SEIR/SEI model to understand the effects of sexually transmitted Zika in Brazil,
Colombia, and El Salvador. The authors did not, however, distinguish between countries as
they assume that the three nations of interest share common parameter values. Additionally,
Towers et al. [54] presented a model that incorporates spatial heterogeneity in populations at
a granular level. Their model focused specifically on the spread of Zika within Barranquilla,
Colombia and included a sexual transmission term, but concluded that the effects are not
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significant enough to sustain the disease in the absence of mosquitoes. An approximation of
the basic reproductive number was obtained using maximum likelihood methods. Finally, a
study of the impact of short term dispersal on the dynamics of Zika virus is analyzed in [57].
The model formulated within [57] does distinguish between asymptomatic and symptomatic
infected populations, and focuses on the estimation of the reproductive number between two
close communities.
In contrast to previous studies, we adopt a more global approach to understanding the
dynamics of the current Zika epidemic and present a model that can be used to study disease
transmission at the country level. We identify differences between countries in regards to
parameter values and reproductive numbers. We discuss the appropriateness of country level
analysis for Colombia, El Salvador, and Suriname and quantify the uncertainty within the
resulting biological parameter values.
In the following section, we develop a Susceptible-Exposed-Infectious-Recovered (SEIR)
/SEI type model which distinguishes between the reported infected population, who are con-
sidered symptomatic, and the unreported infected population, who may be asymptomatic
or experience symptoms that are not severe enough to seek medical attention. The data
available from the Pan American Health Organization (PAHO) serves to motivate the use
of a split infectious population. The number of reported cases of Zika, both suspected and
confirmed, is reported from PAHO by country. Hence, we develop a model for three countries
of interest assuming that the dynamics of the disease within each may be associated with
different parameter values. In Section 5.5, we address the additional complication that the
total population of a country cannot be used as the initial susceptible population due to the
biology and bionomics of the Aedes species and human contact with them, varying in regards
to temperature, humidity [58], sanitation, demographics and elevation [59]. Not everyone
within a country is equally susceptible to the Zika infection due to geographic diversity;
hence, we calculate the unique at-risk population within each country to use as the initial
susceptible population. Using the deterministic model at baseline parameter values, the at-
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risk population we compute yields realistic initial conditions that compare well with PAHO
data. With the initial population sizes for the epidemic in each country known and fixed,
we embed the deterministic system into a stochastic process to quantify the uncertainty of
the parameter values. This method allows us to use biologically valid parameter ranges and
Approximate Bayesian Computation (ABC) methods to obtain parameter distributions that
are distinct to each country. Section 5.6 provides a detailed explanation of our implemen-
tation of the ABC method along with the strengths and weaknesses discovered in applying
this method to our particular model. We summarize the results of the obtained posterior
distributions in Section 5.7. The last section is dedicated to discussion and conclusions.
5.3 Vector-borne SEIR Model with Case Reporting
Figure 5.1 A schematic representation of (5.1), modeling the progression of Zika in human
populations, denoted by green circles, and mosquito populations, represented with red circles.
Susceptible humans start in Sh, and move to Eh, the exposed population, once infected by
a mosquito carrying the virus. After an intrinsic incubation period, exposed individuals
become infectious and transition to either the reported infectious population, Irh , or the
unreported infectious population, Ir. Infectious humans will then move to and remain in Rh
after recovering from the infection. The susceptible mosquito population is denoted Sv. After
transmission occurs from bitting an infectious human, susceptible mosquitoes transition to
the exposed population, Ev. The end of the extrinsic incubation period marks the exposed
mosquitoes shift to the infectious class Iv, where they remain infectious until death.
The spread of Zika relies primarily on interactions between humans and mosquitoes. In
Figure 5.1, members of the at-risk human population, Sh, are bitten by an infectious mosquito
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and become exposed, or infected without yet being infectious, at a rate λh. Humans within
the exposed population, Eh, progress from this state to the infectious compartment at a per
capita rate, νh. Note that there is a portion of infectious humans who are either asymp-
tomatic or experience less severe symptoms, and therefore go unreported. The parameter
ψ denotes the proportion of humans who seek medical assistance and are reported as either
suspected or confirmed Zika patients. Thus, there are two categories for infectious humans:
Irh , the reported infectious population, and Ih, the unreported infectious population. Both




time spent as infectious. Upon recovery, humans acquire lifetime immunity. Similarly, a
member of the susceptible mosquito population, Sv, becomes exposed at a rate λv when
susceptible mosquitoes bite an infectious human, resulting in transmission. The exposed




the average extrinsic incubation period. Once a mosquito is infectious it will remain so for
the duration of its lifespan which can range between 8−35 days [58, 60, 61]. Finally, because
of the long duration of infection for mosquitoes relative to their lifespan, demography (i.e.,
births and deaths) is included within their population dynamics. In total, the system is






= λh(t)Sh − νhEh
dIrh
dt
= ψνhEh − γhIrh
dIh
dt
= (1− ψ)νhEh − γhIh
dRh
dt
= γhIrh + γhIh
dSv
dt
= µvNv − λv(t)Sv − µvSv
dEv
dt
= λv(t)Sv − νvEv − µvEv
dIv
dt
























































Table 5.1 Description of human and mosquito population state variables
Sh Number of susceptible humans
Eh Number of infected humans who are not yet infectious
Irh Number of reported infectious humans
Ih Number of unreported infectious humans
Rh Number of recovered humans
Sv Number of susceptible mosquitos
Ev Number of infected mosquitos who are not yet infectious
Iv Number of infectious mosquitos
The population state variables are described within Table 5.1 and parameters are pre-
sented in Table 5.2. The quantities Nh and Nv represent the total populations of humans
and mosquitoes within the model, and remain constant. We note that the equation for the
evolution of Rh(t) decouples from the system, as it is determined merely by computing the







5.4 Basic reproductive number
We define the basic reproductive number, R0, as the expected number of secondary infec-
tions by a single infectious individual over the duration of the infectious period within a fully
susceptible population [62]. As there is more than one class of infectives involved, we utilize
the next generation method to derive an explicit formula for R0, defined mathematically by
the spectral radius of the next generation matrix [63]. We follow the process in [64] and
define x = [Eh, Irh , Ih, Ev, Iv, Sh, Rh, Sv]
T ; thus reordering the presentation of populations
from the original system to ensure our calculations possess the correct biological representa-
tion. Let Fi(x) be the rate of appearance of new infections in compartment i. We indicate
the rate of transfer of individuals out of compartment i as V −i (x) and the rate of transfer
of individuals into compartment i by all other means as V +i (x). Thus, our system can be
expressed in a condensed version as ẋi = Fi(x) − Vi(x) where Vi(x) = V −i (x) − V +i (x) for
i = 1, ..., 8.
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Table 5.2 Description of parameters within the Zika model. Dimensions are provided in
parentheses on the right most side of the table.
σv Number of times a single mosquito bites a human per unit time.
The average number of days between bites is 1/σv. (Time
−1)
βhv Probability of pathogen transmission from an infectious mosquito to a
susceptible human given that a contact between the two occurs. (Dimensionless)
βvh Probability of pathogen transmission from an infectious human to a
susceptible mosquito given that a contact between the two occurs. (Dimensionless)
νh Per capita rate of progression of humans from the exposed state to
the infectious state. The average duration of the latent period is 1/νh. (Time
−1)
γh Per capita recovery rate for humans from the exposed state to the
infectious state. The average duration of the infectious period is 1/γh. (Time
−1)
ψ Proportion of the infected human population that is reported. (Dimensionless)
νv Per capita rate of progression of mosquitoes from the exposed state
to the infectious state.
The average duration of the extrinsic incubation period is 1/νv. (Time
−1)
µv Density-independent death rate for mosquitoes.
The average lifespan of a mosquito is 1/µv. (Time
−1)
λh The force of infection from infected mosquito to susceptible human.
This is defined as
(# of bites per human by mosquitoes per day)
× (prob. a human is bitten by an infectious mosquito)










λv The force of infection from infected mosquito to susceptible human.
This is defined as
(# of bites on a human per mosquito per day)
× (prob. a mosquito bites an infected human)









Next, we compute F = [∂Fi
∂xj
(x0)] and V = [
∂Vi
∂xj
(x0)] for the exposed and infected com-
partments, namely for 1 ≤ i, j ≤ 5, where x0 = [0, 0, 0, 0, 0, H0, 0, Kv] is the disease free equi-
librium state with H0 and Kv being the initial population sizes of humans and mosquitoes,
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Here, Rhv is the expected number of secondary infections in a fully susceptible human
population resulting from one newly introduced infected mosquito. It is composed of the
product of three terms. The first term, νv
µv+νv
, represents the probability that an exposed
mosquito will survive the extrinsic incubation period. The second term, σv
µv
, is the number of
human bites an infectious mosquito would make if humans were freely available. The third
term, βhv, is the probability of transmission occurrence given that a human is bitten by an
infected mosquito. The number of secondary infections in a fully susceptible population of
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mosquitos resulting from one newly introduced infected human is represented by Rvh. This
value is also formed by the product of three terms. The first, Kv
H0
, is the vector to host ratio.
The σv
γh
term is the maximum number of bites an infectious human will experience before
recovery without impediment to mosquito bites. Finally, given that a susceptible mosquito
bites an infectious human, βvh is the probability of transmission from human to mosquito.
The type reproductive number, or expected number of secondary human cases resulting from
one newly infectious human, is R0
T := (R0)
2 [62].
5.5 Incidence Rates and Parameter Estimation
Although the traditional approach when modeling disease dynamics is to assume the
total population within a country is susceptible, we deviate from this approach. Specifically,
we assume the susceptible population depends on the biology and binomics of the Aedes
species as well as the country’s geography and uniquely calculate the at-risk population
(described in the following section). We then use the at-risk population as the size of
the initial susceptible population within simulations. While the deterministic model (5.1)
captures the dynamics of the epidemic fairly well, we follow the opinion of the authors in [65],
namely that more attention should be paid to how uncertainty in parameter estimates might
affect model predictions. Thus, in Section 5.5.2, we focus on incorporating and quantifying
the uncertainty of the disease process and the parameter values by means of embedding the
deterministic model into a stochastic process.
5.5.1 Calculated At-Risk Population
The data utilized herein was reported by the Pan American Health Organization (PAHO)
[66], and is given by the number of cases, both confirmed and suspected, of Zika per week at
the country level for Colombia, El Salvador and Suriname. Simulations performed by using
the entire country population as the number of initially susceptible humans mischaracterized
the disease dynamics, leading to overestimates in the final size of an epidemic, see Appendix (
Figure 5.13). Since dengue and Zika occur in the same areas, share a common vector and have
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similar asymptomatic rates, we calculate the at-risk population size per country for a Zika
outbreak based on historical data for dengue from 1995 to 2015 within Colombia, El Salvador,
and Suriname [67]. The year of highest incidence for dengue provides an approximation for
the number of susceptible individuals in a fully näıve at-risk population, which coincides
with the dynamics of a newly emerging pathogen, such as Zika, that would spread rapidly
in a completely susceptible population. The World Health Organization (WHO) released a
report on dengue [68], stating “...available results suggest that the actual number of cases of
dengue may range from 3 to 27 times the reported [dengue] number.” Hence, we use a scalar
multiple of the reported number of dengue cases during the highest incidence rate year to
obtain a reasonable at-risk population count for the number of initial susceptible individuals
with regards to a Zika epidemic. Within each of the three countries, the at-risk population
value is strictly less than the total country population.
Table 5.3 indicates the year with the highest incidence rate and the reported number
of cases for that year in each country of interest. See the Appendix ( Figure 5.12) for all
historical data on dengue incidence rates for Colombia, El Salvador and Suriname.
Table 5.3 Reported dengue values from WHO used to compute the at-risk population
Country Highest Incidence Rate Year Reported Number of Cases
Dependent variables / Populations
Colombia 0.00342 2010 157, 152
El Salvador 0.00875 2014 53, 460
Suriname 0.00580 2005 2, 853
We simulated Model (5.1) using the ode45 solver in MATLAB with chosen baseline
parameter values (Table 5.5) while assuming that a single infectious human exists at the
start of the epidemic. The at-risk population size for Colombia is 2.75 times the number
of reported dengue cases from 2010. We estimated the multiplier for the at-risk population
based on the best fit for the currently ongoing epidemic. The at-risk population size for
El Salvador is 1.425 times the number of reported dengue cases from 2014, while the at-
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Table 5.4 Computed At-Risk Population and Other Initial Conditions
Country Original Initial Conditions Shifted Initial Conditions∗ ψ
Dependent variables / Populations
Colombia [432168, 0, 1, 0, 0, 864336, 0, 0] [432163, 1, 0, 1, 4, 864330, 3, 3] 18%
El Salvador [76181, 0, 1, 0, 0, 152362, 0, 0] [75802, 87, 14, 62, 217, 152082, 145, 135] 18%
Suriname [22111, 0, 1, 0, 0, 44222, 0, 0] [22099, 3, 0, 2, 7, 44212, 5, 5] 22%
∗Note: The shifted initial conditions were obtained approximately from Day 38, 118, and 50
of the solution using the original initial conditions for Colombia, El Salvador and Suriname, respectively.
risk population size for Suriname is 7.75 times the number of reported dengue cases from
2005. The initial size of the susceptible mosquito population is double the number of the
at-risk population per country. When starting our analysis with only one infected human,
the simulated epidemic takes several weeks to ramp up to a detectable (reportable) level. If
we begin simulations on the first day that a case is reported, the simulated peak occurs after
the reported peak. Thus, we use shifted initial conditions ( Table 5.4) that correspond to
the population state sizes obtained approximately on day 38, 118, and 50 from the original
simulation using Model (5.1) of the epidemics in Colombia, El Salvador and Suriname,
respectively. We then repeat the process of simulating Model (5.1) using the shifted initial
conditions to obtain solutions for the number of reported cases whose peak reporting weeks
align more closely in time with that of the data. The precise values of the shifted initial
conditions for each country, found in Table 5.4, are of the form [Sh, Eh, Irh , Ih, Rh, Sv, Ev, Iv].
Table 5.5 Ranges and Chosen Baseline Values for Model Parameters
Parameter Baseline Range Reference
Dependent variables / Populations
1/σv 3.85 2− 5.26 [69–71]
βhv 0.54 0.1− 0.75 [46, 62, 71]
1/νh 6 3− 12 [46, 47, 71–76]
1/γh 7 3− 14 [46, 47, 71–76]
ψ 0.18 0.05− 0.3 [45, 46, 71]
βvh 0.75 0.1− 0.75 [46, 62, 71]
1/νv 10.2 4.5− 17 [46, 60, 71, 77, 78]
1/µv 18 8− 35 [58, 60, 61, 71]
104





































Colombia as reported 06.22.2016
(a) Colombia - The model initially fits the
data well but was unable to capture the dy-
namics observed towards the end of the epi-
demic.





































El Salvador as reported 06.22.2016
(b) El Salvador - The model is able to cap-
ture the overall pattern of the epidemic but
with a slightly later peak week.







































Suriname as reported 06.22.2016
(c) Suriname - The model is able to capture
the overall pattern of the epidemic.
Figure 5.2 Solutions of Model (5.1) are plotted in blue along with the weekly Zika data avail-
able from PAHO shown as green circles. These solutions used the shifted initial conditions
(see Table 5.4) and baseline parameters (see Table 5.5). (a) Columbia: cases of Zika were
reported first in Colombia on Epidemiological Week (EW) 32 of 2015. (b) El Salvador: the
first Zika cases were reported on EW 38 of 2015. (c) Suriname: the reporting Zika cases
began on EW 37 of 2015.
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The number of reported cases from our simulations, using the calculated at-risk popu-
lation and shifted initial conditions, are compared to the PAHO Zika data in Figure 5.2.
The solutions, which are similar to the data in peak and general shape, identify reasonable
initial conditions. Although the parameter ranges considered are biologically reasonable, it
is unknown which values within these ranges are the most accurate. To obtain an expected
value for a given parameter and describe the associated uncertainty within this quantity, we
embed the deterministic Model (5.1) into a stochastic process enabling statistical inference.
This process is described in Section 5.5.2.
5.5.2 An Embedded Stochastic Model
Previous literature has provided biologically relevant parameter ranges (see Table 5.5) for
the model. However, to obtain insight as to the distribution of these parameters across their
ranges, we embed the deterministic system of ordinary differential equations (5.1) within a
discrete-time stochastic process to obtain a corresponding stochastic model (5.2, 5.3) and
perform an analysis in a Bayesian paradigm. This approach adds a probabilistic component
to both the contact/infection process and the disease progression process by capturing un-
certainty at each modeling stage, rather than just within the contact/infection process [79].
Therefore, embedding deterministic models into stochastic processes serves to (a) create a
stochastic model informed by population-level dynamics which includes uncertainty in the
entire disease process rather than just due to data collection, (b) more adequately capture
uncertainty present in the modeling framework, which is particularly important in small to
medium sized epidemics, and (c) provide a convenient framework for fast computation of
model parameters. The process by which we embed Model (5.1) into a stochastic process,
[36], is summarized in the following paragraphs.
Previously, we obtained specific rates for the transfer of both humans and mosquitos
between their respective compartments, and these can be used to inform the stochastic
analogues of these parameters. Throughout, we impose that the new model be conservative,
i.e. Sh+Eh+Irh+Ih+Rh = Nh and Sv+Ev+Iv = Nv where Nh and Nv are the total human
106
and mosquito populations, respectively. The assumption of conservation within the human
population is plausible as the time span of the epidemic is much smaller than the average
lifespan of a human. We hold the mosquito population as constant for the convenience of
calculations and analysis. To approximate a continuous SEIR type model, we account for
all events/transitions that may occur during time interval (i, i + hi] to be assigned to the
related compartment on day i. Thus, the rate of change for a given population size can be
approximated by the difference between the previous and current time steps. The model
now takes the form
Si+hi = Si − E∗i+hi








Ii+hi = Ii + (1− ψ)I∗i+hi −RI
∗
i+hi




Svi+hi = Svi + dEv
∗
i+hi
+ dIv∗i+hi − Ev
∗
i+hi
Evi+hi = Evi + Ev
∗
i+hi
− Iv∗i+hi − dEv
∗
i+hi


































We index time by i, and the temporal offset, hi, which may not be constant but is known.
All quantities represent counts, and quantities denoted by an asterisk represent transition
counts. In regards to the terms ψI∗i+hi and (1 − ψ)I∗i+hi , the parameter ψ may yield values
which are not integer counts. To be more liberal with the reporting size we calculated the
smallest integer not less than the corresponding value of ψI∗i+hi . To be more conservative
with under-reporting size we calculated the largest integer not greater than the corresponding
value of (1−ψ)I∗i+hi . When individuals can transition into a compartment via multiple routes,




), two letters are used to denote the transition. In these cases, the first
letter denotes to which compartment the individual transitions and the second denotes the
compartment from which the individual transitions. The transition compartments which
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represent birth/death counts of the mosquito popultion on day i + hi are denoted, dEv
∗
i+hi
and dIv∗i+hi . Note that these values are drawn based on the calculated population sizes at
time i+ hi. The compartments are labeled as follows: S - susceptible humans, E - latently
infected humans, Ir - infectious reported humans, I - infectious unreported humans, R
- recovered humans, Sv - susceptible mosquitoes, Ev - latently infected mosquitoes, Iv -



























Evi+hi , 1− exp(−µhhi)
)
, dIv∗i+hi ∼ Bin
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5.6 ABC Algorithm and Computation
Previous investigations [45, 46, 62, 77] have established biologically accepted ranges for
the parametersΘ = [σv, βhv, νh, ψ, βvh, νv, µv] used within (5.1), but the conversion of Model
(5.1) to Model (5.2, 5.3) will incorporate uncertainty into the disease process, and thus the
values of these parameters. The stochastic model (5.2, 5.3) also allows for Bayesian inference
on parameter posteriors which have the form
f(Θ|Y ) ∝ f(Y |Θ)π(Θ)
where f(Y |Θ) is the stochastic data model, which for fixed values of Θ can be used to
generate the random epidemic process, and π(Θ) is the prior distribution of the parameters.
Thus, given both the data model and the prior distribution, we are able to calculate the
posterior distribution f(Θ|Y ) up to a proportionality constant. This serves to update the
distribution of the biologically accepted parameter ranges based on the actual epidemic data
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which we denote as Y .
The data model is constructed as a product of binomials with different sample sizes and
probabilities across every time point. Determining a Maximum Likelihood Estimate (MLE)
to provide a point estimate and standard deviation for parameters may provide estimates
outside of the valid biological ranges. In SEIR models, Markov Chain Monte Carlo (MCMC)
methods produce parameter autocorrelations in chains which becomes problematic for tun-
ing. We can avoid these obstacles by using Approximate Bayesian Computation (ABC).
This method was introduced by [41] to obtain an approximation of the true posterior distri-
bution, f(Θ|Y ). ABC samples from the posterior by randomly selecting parameter values
from the prior that could adequately generate the data. In particular, random draws, Θ∗,
from the prior distribution produce generated data sets, X, which are then compared to a
given epidemic data set, Y , by means of a chosen distance metric, ρ(X, Y ). Those values of
Θ∗ that generate data sets which fit the given data will be accepted as valid draws from the
posterior distribution, and this implicitly conditions the posterior on Y . The algorithm of
the computation is as follows, whereN is the total number of accepted generated data setsX:
For j ≤ N
1. Draw Θ∗ ∼ Unif(ak, bk), where (ak, bk) is the corresponding parameter range found in
Table 5.6 for all k = 1, ..., 7.
2. Generate X, time series data of the number of reported infectives, from Model (5.2,
5.3)
3. Calculate fitness of data using ρ(X, Y )
4. Set Θ[j] ← Θ∗ if ρ(X, Y ) ≤ ǫ and set j ← j + 1 else return to Step 1.
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Table 5.6 Ranges for Uniform Distributions
Parameter Range









Note: We expand the ranges given in Table 5.5 as these are educated approximations and
there is uncertainty with regards to the true range of most of these parameters.
The metric, ρ(X, Y ), is considered a distance between the generated data set, X, and
the observed data set, Y , typically based on sufficient statistics of the parameter space Θ.
If ρ(X, Y ) is small enough, i.e., ρ(X, Y ) ≤ ǫ for some fixed small value ǫ > 0, then
f(Θ|ρ(X, Y ) ≤ ǫ) ≈ f(Θ|Y ).
One often uses sufficient statistics in defining ρ(X, Y ). These are statistics for which
the data distribution conditioned on the sufficient statistic is free of Θ (e.g., the sufficient
statistic contains all information about Θ that the full data set contains). By definition, the
full data set is a sufficient statistic for Θ. Since a sufficient statistic of lower dimension than
the full data set cannot be readily computed for our model, we consider a pointwise envelope
metric comparing point by point the L1-norm at every time step. Thus, if every data point
of X and Y is close, then it directly follows that any statistics computed from X and Y ,
including sufficient statistics, will also be close. For the ABC method, the exact posterior
distribution of Θ can be found by accepting the simulated data set in which X = Y . This
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is computationally infeasible, however, so we instead consider X, such that Xt
Yt
∈ (ǫ1, ǫ2)
for all time steps t with a corresponding peak week and epidemic duration to Y , as an
acceptable epidemic. We call (ǫ1, ǫ2) the envelope of tolerance around the observed data
set, Y , which is a common method for assessing a stochastic SEIR model fit [35, 37, 42].
In Figure 5.3, the observed data set is compared to randomly generated data sets without
calculating a metric for validation of the drawn parameter values. Figure 5.3 shows that many
randomly drawn and biologically accepted values of Θ generate epidemic outcomes which
have distinctly different characteristics than the observed epidemic. Conversely, Figure 5.4
demonstrates that epidemic outcomes of the accepted Θ∗ values generate epidemics with
similar characteristics to that of the observed epidemic in regards to the total number of new
infections each day, peak week occurrence, and peak value. Figure 5.4(b) and Figure 5.4(c)
show generated epidemics similar to the data in both peak and duration. Note that this
does not occur in Figure 5.4(a). The accepted parameter values obtained using the ABC
method yield outbreaks which vary greatly in peak occurrence, leading us to conclude that
the dynamics of the country-level data are different than those in the deterministic model.
Therefore the ABC method does not generate infectious curves similar to the Colombia
data. Figure 5.4(a) was generated from acceptances using an envelope of (1/20, 20). A
tighter envelope of (1/10, 10) was computed; however, the method ran for approximately 35
days to obtain the same number of acceptances as the (1/20, 20) envelope with no visible
changes in the same plot as Figure 5.4(a). Because acceptances for tighter envelopes are
not possible, we can conclude the model is improperly specified to capture the dynamics of











































































Figure 5.3 Each subfigure contains the results of using randomly drawn parameter vectors
in Model (5.2, 5.3) to generate outcomes of the epidemic in which a metric is not applied.
For all three countries the biologically accepted parameter values generate epidemics that













































































Figure 5.4 Each subfigure compares the stochastic model epidemic outcomes from 500 of
the 10,000 accepted randomly generated parameter vector draws (gray) and the observed
epidemic in each country (black). The envelope size is (1/20, 20) for Colombia (a) with the
occurrence of peak week within ±4 weeks of the known peak week and the peak number
of new infections less than or equal to a 20% deviation from the true value. The envelope
size for El Salvador (b) is (2/3, 2) with the occurrence of peak week within ±2 weeks of
the known peak week and the peak number of new infections less than or equal to a 5%
deviation from the true value. The data from Suriname (c) was compared to generated data
with an envelope size of (1/4, 4) and the occurrence of peak week within ±2 weeks of the
known peak week and the peak number of new infections less than equal to a 5% deviation
from the true value.
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(a) El Salvador - ψ













(b) El Salvador - R0










(c) Suriname - ψ












(d) Suriname - R0
Figure 5.5 Subfigures (a) and (c) display the kernel density plots of the proportion of reported
infectious, ψ, with various envelope sizes for El Salvador and Suriname, respectively, while
subfigures (b) and (d) show the kernel density plots of the reproductive number, R0 for El
Salvador and Suriname, respectively. As the legends indicate, an envelope size of (2/3, 2)
is displayed by the black curve, an envelope size of (1/4, 4) is displayed in blue, the red
curve represents an envelope size of (1/10, 10), and similarly the green curves indicate an
envelope size of (1/20, 20) using green. Note that envelopes of all four sizes were able to
generate acceptances from the El Salvador data while the data from Suriname only allowed
for acceptance to be generated from envelope sizes of (1/4, 4), (1/10, 10), and (1/20, 20).
Figure 5.5 depicts the effect of generating accepted epidemics with smaller and smaller
envelopes of tolerance on the posterior distributions. We plot the kernel densities of both the
reporting rate, ψ, and reproductive number, R0, distributions for El Salvador and Suriname.
While only two parameters are shown here, the same observations are found in the kernel
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density plots of the other parameters of interest. We see in Figure 5.5 that envelopes of
various size produce similar but different kernel densities, with the tighter envelopes pro-
ducing a more peaked density distribution. A slight shift in the peak of the kernel densities
is observed in Figure 5.5(a) and Figure 5.5(d). This would indicate the need to shrink the
envelope further to obtain an estimation that is closer to the true posterior distribution.
However, attempts to generate data sets satisfying tighter envelopes could not produce ac-
ceptances, indicating that these envelope sizes are the best possible fits of the stochastic
SEIrIRSvEvIv model to the observed country-level data. Further analysis would require
refining the dynamics of Model (5.1) and Model (5.2, 5.3) or using data at a more refined
spatial scale.
5.7 Results
We assigned uniform distributions to the accepted biological ranges found in Table 5.6.
After 10,000 acceptances from the ABC algorithm, the histograms and kernel densities for
selected parameters from El Salvador are given in Figure 5.6 and Figure 5.8. Selected
parameters from Suriname are given in Figure 5.7 and Figure 5.8. Figure 5.9 displays the
number of reported cases from the generated epidemics based on 10,000 accepted parameter
values. The time series of the number of total cases during the generated epidemics of
both reported and unreported infectives is found in Figure 5.10. The histogram and kernel
density plots of the total number of Zika virus cases, reported and unreported are shown in
Figure 5.11.
Table 5.7 Selected Parameter Statistics for El Salvador
ψ σvβhv σvβvh
Dependent variables / Populations
mean 0.1654 0.2808 0.3053
median 0.1593 0.2124 0.2130
mode 0.1501 0.1372 0.1091


















(a) El Salvador - ψ
















(b) El Salvador - σvβhv














(c) El Salvador - σvβvh
Figure 5.6 ABC generated histograms and kernel density plots for the reporting rate, ψ,
















(a) Suriname - ψ














(b) Suriname - σvβhv














(c) Suriname - σvβvh
Figure 5.7 ABC generated histograms and kernel density plots for the reporting rate, ψ,
the force of infection for the human population, σvβhv, and mosquito population, σvβvh in
Suriname.
Table 5.8 Selected Parameter Statistics for Suriname
ψ σvβhv σvβvh
Dependent variables / Populations
mean 0.1877 0.1705 0.4352
median 0.1777 0.1429 0.3365
mode 0.1693 0.0998 0.2069

































(b) Suriname - R0
Figure 5.8 ABC generated histograms and kernel density plots of the Reproductive Number
for El Salvador (a) and Suriname (b).I NEED MORE SPACE BETWEEN THESE
STUPID FIGURES!!!!!@ KEEP UP THE GOOD WORK WHITE SPACE.KAJSD ;LFK-
JAS;LDKJFPAOIWEJRF;ASLKDFN;LASKJDF;ALSKJDF;LAS KJDF;ALKSJDF;LA
KJSDF; LAKSJ
Table 5.9 Reproductive Number Statistics per Country
R0 El Salvador Suriname





95% C.I. [1.4664, 3.1658] [1.6526, 3.4704]
Note: The median2 is an approximation of the type of reproduction number (i.e. human-to-human)
as opposed to R0, which is the single generation reproduction number.
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Total Reported Zika virus cases


























Total Reported Zika virus cases

















Figure 5.9 Histogram with kernel density plot of the total number of reported Zika virus












































































Figure 5.10 Generated time series data (grey) for the total number of Zika cases (reported
+ unreported) from the ABC-accepted parameter values as compared to the observed data
(black) reported by PAHO for El Salvador (a) and Suriname (b).
118
Total Zika virus cases













Total Zika virus cases

















Figure 5.11 Histogram and kernel density plot of generated total number of Zika virus cases,
both reported and unreported, from the ABC accepted parameter values for El Salvador (a)
and Suriname (b).
Table 5.10 Statistics for the Generated Total Cases (Reported and Unreported) per Country
El Salvador Reported Cases Total Cases




95% C.I. [9606,15321] [67317, 75889]
PAHO data 11825
Suriname Reported Cases Total Cases




95% C.I. [3013, 5697] [19853,221027]
PAHO data 3042
5.8 Conclusion and Discussion
Within the present study, a new stochastic model was formulated to describe the spread
of the Zika virus within Colombia, Suriname, and El Salvador. The variability in per capita
susceptibility within each country was introduced by uniquely calculating the at-risk popu-
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lation based on historical data for dengue virus, whose epidemic characteristics are similar to
that of Zika. The initial population state sizes were fit to this data in order to create similar
values of weekly reported cases of Zika, both suspected and confirmed, to those reported by
the PAHO using baseline values of parameters to evaluate Model (5.1). Once the at-risk
population was estimated, the initial population state sizes for these nations were fixed in
order to estimate parameter values and obtain more informative distributions than the ac-
cepted biological parameter ranges. The deterministic system (5.1) was then embedded into
a stochastic process to obtain a more general stochastic model (5.2, 5.3). For each of the
three nations, an ABC algorithm was implemented using (5.2, 5.3) to compute approximate
posterior distributions of the parameters conditioned on the data. By obtaining these pos-
terior distributions, the uncertainty in parameter values for each country can be quantified
by way of informative statistics, such as the mean, mode, median and variance, to more
accurately describe rates within the system.
Properties of the disease within El Salavador and Suriname were accurately described by
the model. El Salvador is estimated to have a mean reporting rate of 16.5% which is near
the upper bound of the previous estimate of [46] with a credible interval of [12.5%, 22%].
The mean values of the forcing terms, λh and λv, are approximately 0.28 and 0.31 with
credible intervals of [0.0191, 0.7782] and [0.0119, 0.9244], respectively. Suriname has a mean
reporting rate greater than the predicted interval of [46] at 18.8% with a credible interval
of [13%, 27%]. The forcing terms of Suriname, λh and λv, had mean values of 0.17 and
0.43 with credible intervals of [0.0165, 0.4054] and [0.0429, 1.1241], respectively. The basic
reproductive number, R0, was defined such that R0
2 yields the number of secondary human
infections within a fully susceptible population arising from a single new human infection.
In Suriname, the mean value of R0
2 was 5.31, while the mean reproductive number was 4.35




Though this analysis has provided additional insight into the spread of the disease, our
methods were unable to accurately estimate the aforementioned statistics for Colombia (see
Section 5.6) as the ABC method revealed a poor fit for the data obtained from this nation.
One possible reason for this poor fit could be the appearance of a second peak in the epidemic,
see Figure 5.2(a). While there is a distinct and large peak during EW 26, a smaller second
peak occurs during EW 34. This second peak may result from reporting error as this data
was in no way cleaned once obtained from the PAHO website. Another possible explanation
is a second outbreak in a disjoint location from the first outbreak. In particular, the extreme
topographical variations within Colombia could lead to a delay in the spread of the disease
across the entire country. Thus, we conclude that the epidemiological characteristics of Zika
in Colombia must be studied at a more granular spatial level, differentiating amongst regions
or even counties and cities.
We also estimated the total number of infected people in El Salvador to be 72,721 (with
an estimated 12,107 reported cases) and the total number of people infected in Suriname to
be 21,390 (with an estimated 4,132 reported cases). So, about 95% of the at-risk (high-risk)
populations were infected by the end of the outbreak. The predicted reported country-
level incidence for El Salvador is 0.0019 and for Suriname is 0.0073. However, the true
country-level incidence for El Salvador is predicted to be 0.0119 while for Suriname it is
0.0396 assuming total populations of 6,117,145 and 540,612, respectively. From a public
health perspective, our model indicates that about 6 times as many people were infected
than were reported in El Salvador and 5 times as many were infected than were reported in
Suriname. Depending on the percent of the at-risk population that was pregnant during the
outbreak, our model suggests that a larger number of birth defects than indicated by the
reported number of cases could be expected in these countries. Interestingly, although the
values for the mosquito extrinsic incubation period and mosquito lifespan had relatively wide
ranges even among mean, median, and mode values, the probability of a mosquito surviving
the incubation period (Figure 5.14 and Figure 5.15) was quite similar across statistics and
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countries at about 60%. This corresponds to the extrinsic incubation period lasting around
2/3 of the average mosquito lifespan. A major difference between predicted parameter values
for El Salvador and Suriname occurs in the transmission probabilities. While the values for
βhv and βvh for El Salvador were similar (both estimated to be about 0.42), in Suriname,
the mosquito-to-human probability of transmission, βhv was consistently less than half that
of the human-to-mosquito transmission, βvh, with a median of 0.21 and 0.56, respectively.
Since these terms capture many intrinsic uncertainties in the transmission process, it is hard
to interpret the meaning of this difference. It could be an artifact of the model or could
indicate a reduced efficiency of the mosquitoes in Suriname in passing on the virus.
In conclusion, our research provides important parameter estimates for the spread of Zika
in El Salvador and Suriname, along with uncertainty quantification and credible intervals
for those parameters. We estimated the basic and type reproduction numbers and the total
number of people infected - quantities needed to inform assessments of economic cost and
risk, among other factors. We found that the type reproduction number is higher in Suri-
name than in El Salvador, indicating a higher risk in Suriname. This could be explained
by differences in climate between the two countries or in other socio-economic or geographic
factors affecting mosquito-borne disease transmission. Additionally, our methods could be
applied to other countries or regions experiencing outbreaks to estimate region-specific pa-
rameters and provide decision makers with important information about surveillance and
control both at present and in the future. Another advantage of this method is that it
can indicate what scale is appropriate for these calculations. For example, we found that a
country-level analysis of the Colombia data was not appropriate. In the future, it would be
interesting to apply the model to a regional Colombia data set.
In future studies, the initial population state sizes obtained in the calculations of the
respective at-risk populations could be considered parameters themselves. Hence, one could
perform a statistical analysis on acceptable ranges for such initial values to quantify the
uncertainty of these populations. For instance, this could be done by generating a posterior
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distribution for the initial susceptible population for each country, as well as the parameters
in the system. Additionally, the mosquito population for each country was assumed to be
constant for convenience. However, utilizing a more realistic model of the total mosquito
population which changes in time (similar to the methods in [62]) may yield different results,
and this would also be a suitable direction for future research. Finally, the recovery period,
1/γh, was held constant in the current study due to the assumption that its mean value had
been medically established. Still, another investigation using the methods developed herein,
but considering a uniformly-distributed prior for the recovery period, may provide better
insight into the distribution and expected value of this period. We conclude that additional
studies are needed to fully understand Zika virus transmission dynamics. However, our
research suggests that the reporting rates in El Salvador and Suriname are quite low and
thus, additional surveillance systems may be needed to measure the true burden of Zika in
these countries.
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5.10 Appendix
This section provides the figures mentioned but not shown in the previous work within
Chapter 5 of this thesis in regards to the study of the Zika virus in El Salvador and Suriname.
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Figure 5.12 Reported rates of incidence are calculated based on the number of reported cases
documented [67] divided by the reported country population in the corresponding year [81].









































Colombia as reported 06.22.2016
(a) Colombia






































El Salvador as reported 06.22.2016
(b) El Salvador




































Suriname as reported 06.22.2016
(c) Suriname
Figure 5.13 The time series for the number of reported infectives as calculated using Model
(5.1) with the initial number of susceptible people equal to the total population (solid blue
line) as compared to the PAHO data (dotted green) as reported 06.22.2016 per country. The
total populations as reported for 2015 are 48,010,049 (Colombia), 6,117,145 (El Salvador),


















(a) El Salvador - 1/σv
















(b) El Salvador - βhv




















(c) El Salvador - 1/νh
















(d) El Salvador - βvh
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(f) El Salvador - 1/µv
















(g) El Salvador - νv
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(a) Suriname - 1/σv
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Table 5.11 Statistics for the Other Parameter Values for El Salvador
1/σv βhv 1/νh βvh 1/νv 1/µv
νv
µv+νv
Dependent variables / Populations
mean 1.6894 0.4201 5.5626 0.4260 8.4171 14.9655 0.6206
median 1.3874 0.3817 3.8095 0.3882 7.0799 11.4532 0.6315
mode 0.7397 0.0851 2.5506 0.0760 4.8253 8.4276 0.6451
95% C.I. [0.5004, 3.8294] [0.01274, 0.9302] [2.0001, 15.5402] [0.0104, 0.9289] [4.0001, 17.0355] [7.1432, 35.9220] [0.3475, 0.8832]
Table 5.12 Statistics for the Other Parameter Values for Suriname
1/σv βhv 1/νh βvh 1/νv 1/µv
νv
µv+νv
Dependent variables / Populations
mean 1.6819 0.3004 6.6144 0.5602 8.3111 16.1174 0.6369
median 1.3684 0.2141 4.8592 0.5657 6.9234 12.4293 0.6453
mode 0.7375 0.0702 2.7695 0.8657 4.8375 8.7023 0.6521
95% C.I. [0.5002, 3.8328] [0.0101, 0.8456] [2.0001, 16.8145] [0.1358, 0.9985] [4.0000, 16.9617] [7.1467, 38.2319] [0.3699, 0.8961]


















(a) El Salvador - Rhv

















(b) El Salvador - Rvh














(c) Suriname - Rhv




















(d) Suriname - Rvh
Figure 5.16 Displayed are the individual to individual reproductive ratios. For El Salvador
the mosquito to human ratio histogram and kernel density is (a) while the human to mosquito
ratio histogram and kernel density is (b). (c) and (d) show the histogram and kernel density
plots of the mosquito to human and human to mosquito ratios for Suriname, respectively.
Table 5.13 Statistics for the Individual to Individual Reproductive Numbers
El Salvador - Rhv El Salvador - Rvh Suriname - Rhv Suriname - Rvh
Dependent variables / Populations
mean 2.4588 4.2743 1.6667 6.0925
median 1.5509 2.9813 1.1414 4.7115
mode 0.9238 1.5273 0.6250 2.8961




In this thesis, we examined the contributions mathematical modeling can provide for non-
invasive biological research. Specifically, we used the law of mass action to model, analyze
and simulate disease dynamics of HIV, Ebola, and Zika virus.
In Chapters 2 and 3, a mass action term was utilized in two different systems of Ordinary
Differential Equations to capture the rates of change for healthy T cells, infected T cells and
virion populations. We found in the HIV model first presented that the ability for HIV to
rapidly mutate complicates the efficacy of ART drugs, implying that RTIs alone are not
strong enough to counteract the emergence of drug resistant strains. Sensitivity analysis
indicated that the parameters which drive the spread of HIV within CD4+T cells varies
with transition between clinical stages of the disease progression making early intervention
difficult. We see inclusion of the homeostatic proliferation term in the standard viral dy-
namics model presented in Chapter 2 created bistability, within certain parameter regimes,
demonstrating dependence of the system on initial viral load exposure in regards to long
term dynamics. The discovery of a hopf bifurcation may prove useful in understanding the
source of biological phenomena, referred to as oscillatory blips, observed in clinical trials.
The spread of Ebola and Zika virus at the population level was examined in Chapter 4
and 5. A law of mass action term was used within systems of ODEs once again, but in these
chapters the system which modeled each disease was embedded into a stochastic process to
incorporate uncertainty into the disease process as well as the values of the parameters of
interest. While the method of embedding is not novel, the derivation of the multinomial dis-
tribution within the stochastic Ebola model is. This distribution enabled simulations to be
maintained at the population level which coincides with the data provided as well as compu-
tationally efficient. An underutilized approach to obtaining posterior distributions was taken
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in the application of the Approximate Bayesian Computation enveloping method showing
the strength of this method in regards to producing multimodal posterior distributions.
The work presented in this thesis motivates a continuation of applications of these meth-
ods to further examine these and other infectious diseases. Future applications include
estimating the number of pregnant women in a particular population during the Zika virus
outbreak to inform the medical community of the magnitude of preparedness needed in
addressing newborns adversely effected by the disease. Mitigation strategies could be incor-
porated into both the Ebola and Zika virus models to more closely examine the effectiveness
of these procedures in reducing the number of people impacted during an outbreak. Research
within the area of mathematically modeling infectious diseases will continue to develop as
we work toward eradicating these and other diseases.
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Larre, et al. Guillain-barré syndrome outbreak associated with Zika virus infection in
french polynesia: a case-control study. The Lancet, 387(10027):1531–1539, 2016.
[52] Eric D., Ortenzio, Sophie Matheron, Xavier de Lamballerie, Bruno Hubert, Géraldine
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